UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
AMENDMENT TO FORM 10-K ANNUAL REPORT
FILED PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended Commission file number
December 31, 2001 1-1225
----------------- ------
WYETH
-----
(Exact name of registrant as specified in its charter)
Delaware 13-2526821
- ----------------------------------------- ----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification
incorporation or organization) Number)
Five Giralda Farms, Madison, NJ 07940-0874
- ----------------------------------------- ----------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including
area code (973) 660-5000
--------------
Securities registered pursuant to
Section 12(b) of the Act:
Name of each exchange on
Title of each class Which registered
- ----------------------------------------- ----------------------------------
$2 Convertible Preferred Stock, $2.50
par value New York Stock Exchange
- ----------------------------------------- ----------------------------------
Common Stock, $0.33 - 1/3 par value
(including Preferred Stock Purchase
Rights) New York Stock Exchange
- ----------------------------------------- ----------------------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
-----
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
State the aggregate market value of the voting stock held by nonaffiliates of
the registrant. The aggregate market value shall be computed by reference to the
price at which the stock was sold, or the average bid and asked prices of such
stock, as of a specified date within 60 days prior to the date of filing.
Aggregate market value at November 29, 2002 $50,950,994,551
Indicate the number of shares outstanding of each of the registrant's classes of
common stock, as of the latest practicable date.
Outstanding at
November 29, 2002
-----------------
Common Stock, $0.33 - 1/3 par value 1,325,813,025
EXPLANATORY NOTE
This Form 10-K/A is being filed to amend Wyeth's (the Company) Annual Report on
Form 10-K for the year ended December 31, 2001 (the 2001 Form 10-K) to (1)
include under Item 15 an audit report by PricewaterhouseCoopers LLP (PwC) with
respect to Wyeth's financial statements for its 2001 fiscal year and (2) to
include as an exhibit the Consent of Independent Auditors,
PricewaterhouseCoopers LLP, required by Item 601 of Regulation S-K of the
Securities and Exchange Commission (the Commission).
Wyeth's financial statements contained in the 2001 Form 10-K were audited by
Arthur Andersen LLP, whose audit report with respect to such financial
statements was included therein. On March 13, 2002, the Board of Directors of
Wyeth, upon recommendation of its Audit Committee, made a determination not to
further engage Arthur Andersen as the Company's independent public accountants
and engaged PwC to serve as the Company's independent public accountants for the
fiscal year 2002. The appointment of PwC was ratified by the stockholders of
Wyeth at the Company's 2002 Annual Meeting of Stockholders held on April 25,
2002.
The Company engaged PwC to perform an audit of its financial statements for the
fiscal year 2001. PwC has completed this audit, which resulted in no revisions
to the Company's financial statements for such period.
In addition, subsequent to the filing of the 2001 Form 10-K, the staff of the
Commission engaged in a review of Wyeth's periodic filings. As a result of this
review process, Wyeth agreed to provide added or expanded disclosures with
respect to certain matters to be included in future filings with the Commission.
This Form 10-K/A includes such additional disclosures where appropriate and,
accordingly revises Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operations and Item 8 - Financial Statements and
Supplementary Data of the 2001 Form 10-K as follows (no financial statement or
footnote balances have been restated or amended):
Item 7: Under the heading Results of Operations - Net Revenue, net revenue
product fluctuation charts have been added to provide quantitative
data on the increases / (decreases) of certain of the Company's major
products for its pharmaceutical and consumer health care operating
segments for both 2001 vs. 2000 and 2000 vs. 1999 comparisons.
Item 8:
- Note 1 - Summary of Significant Accounting Policies has been revised
to include (1) under Property, Plant and Equipment, the range of
estimated useful lives for the Company's different asset
categorizations, (2) under Rebates and Sales Incentives, a statement
clarifying the Company's policy of recognizing the cost of rebates and
sales incentives, and (3) the Company's research and development
expenses accounting policy under Research and Development Expenses.
- Note 2 - Acquisitions, Divestitures and Discontinued Operations has
been revised to clarify how the Company determined the loss on the
sale of its Cyanamid Agricultural Products business to BASF.
- Note 14 - Subsequent Events has been added to disclose all material
subsequent events that have occurred between the filing of the 2001
Form 10-K on March 29, 2002 and the filing of this Form 10-K/A.
The information contained in this Form 10-K/A modifies and supersedes the
corresponding information in the 2001 Form 10-K. Except as specifically
described in this Form 10-K/A, the 2001 Form 10-K, as amended by this Form
10-K/A, continues to speak as of the date it was initially filed with the
Commission, March 29, 2002.
Information regarding the Company for the period subsequent to December 31, 2001
is contained in our Quarterly Reports on Form 10-Q for the quarters ended March
31, 2002, June 30, 2002 and September 30, 2002 and our Current Reports on Form
8-K filed on January 8, 2002, March 11, 2002, March 13, 2002, March 18, 2002,
July 29, 2002, August 8, 2002 and December 9, 2002.
PART II
-------
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following commentary should be read in conjunction with the Consolidated
Financial Statements and Notes to Consolidated Financial Statements contained in
Item 8 of this Annual Report on Form 10-K/A.
Results of Operations
Basis of Presentation
- ---------------------
Management's discussion and analysis of results of operations for 2001 vs. 2000
and 2000 vs. 1999 are presented on an as-reported basis, except for Net revenue
variation explanations between 2000 and 1999, which are presented on an
as-reported and pro forma basis. Effective January 1, 2000, the financial
results of certain pharmaceutical subsidiaries in Japan and India, which
previously were included on an equity basis, were consolidated in the financial
results of the Company. The financial results of Immunex, which previously were
consolidated in the financial results of the Company, were deconsolidated and
included on an equity basis, retroactive to January 1, 2000, within the
pharmaceuticals segment. Accordingly, alliance revenue was recorded in 2001 and
2000 for co-promotion agreements between the Company and Immunex. The 2000 vs.
1999 pro forma net revenue percentage changes reflect the respective
consolidation and deconsolidation of these subsidiaries and include alliance
revenue from Immunex, assuming all transactions occurred as of January 1, 1999.
Neither the consolidation nor the deconsolidation of these subsidiaries had any
effect on income from continuing operations in 2000.
In addition, the Company early adopted new authoritative accounting guidance
as of January 1, 2001 reflecting certain rebates and sales incentives (i.e.,
coupons and other rebate programs) as reductions of revenues instead of selling
and marketing expenses. Financial information for all prior periods presented
has been reclassified to comply with the income statement classification
requirements of the new guidance. These reclassifications had no effect on total
net revenue growth between the periods presented. However, consumer health care
net revenue growth for 2000 vs. 1999 was 3% without the reclassification
adjustments as compared with the as-reported growth rate of 4%.
Net Revenue
- -----------
Worldwide net revenue increased 7% to $14.1 billion for 2001 on an as-reported
basis. Worldwide net revenue increased 12% to $13.2 billion for 2000 on an
as-reported basis. After adjusting for the consolidation and deconsolidation of
the subsidiaries identified above, and including alliance revenue from Immunex,
pro forma worldwide net revenue for 2000 increased 13% due primarily to higher
worldwide sales of pharmaceuticals.
1
The following table sets forth 2001, 2000 and 1999 worldwide net revenue
results by operating segment together with the percentage changes in
"As-Reported" and "Pro Forma" (where applicable) worldwide net revenue from
prior years:
2001 vs. 2000 2000 vs. 1999
------------- ---------------------------
Years Ended December 31, As-Reported
(Dollar amounts in millions) -------------------------------------- % Increase As-Reported Pro Forma
Net Revenue 2001 2000 1999 (Decrease) % Increase % Increase
- --------------------------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $11,716.5 $10,772.6 $9,469.7 9 % 14 % 16 %
Consumer Health Care 2,412.0 2,441.1 2,345.4 (1)% 4 % 4 %
-----------------------------------------------------------------------------------------
Consolidated Net Revenue $14,128.5 $13,213.7 $11,815.1 7 % 12 % 13 %
=========================================================================================
2001 vs. 2000
Worldwide pharmaceutical net revenue increased 9% (10% for human
pharmaceuticals) for 2001. Excluding the negative impact of foreign exchange,
worldwide pharmaceutical net revenue increased 11% for 2001. U.S. pharmaceutical
net revenue increased 15% for 2001 due primarily to higher sales of Protonix
(introduced in the 2000 second quarter), Prevnar (introduced in the 2000 first
quarter), Effexor XR (as a result of higher volume and market share of new
prescriptions as well as expanded indications), Premarin products and Cordarone
I.V., and alliance revenue offset, in part, by lower sales of Ziac (due to
generic competition) and generic products (discontinuance of certain oral
generics).
International pharmaceutical net revenue decreased 1% for 2001 due primarily
to lower sales of Meningitec and animal health products offset, in part, by
higher sales of Effexor XR (as a result of higher volume and market share of new
prescriptions, as well as expanded indications), Enbrel (internationally the
Company has exclusive marketing rights to Enbrel), Zoton and infant
nutritionals. Sales of Meningitec, the Company's meningococcal meningitis
vaccine, decreased as compared with the prior year, as it was used in 2000 to
vaccinate nearly all children and adolescents in the United Kingdom. The product
currently is being launched in 10 other European countries; however, the Company
does not currently anticipate that any of these markets, individually, will
provide sales volume equivalent to that generated in the United Kingdom. The
decline in animal health product revenues was due primarily to a general
continued weakening in the livestock markets and continuing concerns about
foot-and-mouth and mad cow diseases.
Worldwide consumer health care net revenue decreased 1% for 2001. Excluding
the negative impact of foreign exchange, worldwide consumer health care net
revenue was unchanged for 2001. U.S. consumer health care net revenue was
unchanged for 2001 as a result of higher sales of Chap Stick, Caltrate and Advil
being offset by lower sales of cough/cold/allergy products and Flexagen.
International consumer health care net revenue decreased 3% for 2001 due
primarily to the divestiture of two international non-core products which
occurred early in 2001, as well as lower sales of cough/cold/allergy products.
These decreases were partially offset by higher sales of Centrum products,
Caltrate and Advil.
2
The following table sets forth the significant worldwide pharmaceutical and
consumer health care net revenue product fluctuations for the twelve months
ended December 31, 2001 compared with the same period in the prior year:
Pharmaceuticals Consumer Health Care
- -------------------------------------------- --------------------------------------------------
2001 vs. 2000 2001 vs. 2000
---------------------- ----------------------
($ millions) $ Increase % Increase ($ millions) $ Increase % Increase
Products (Decrease) (Decrease) Products (Decrease) (Decrease)
- --------------------- ---------- ---------- --------------------------- ---------- ----------
Protonix $416.3 287% Chap Stick $15.7 13%
Effexor 382.9 33% Caltrate 15.3 11%
Prevnar 337.6 73% Centrum 10.3 2%
Cordarone 66.4 33% Advil 6.7 1%
ReFacto 56.2 62% Cough/cold/allergy products (30.7) (6)%
Generics (133.3) (28)% Flexagen (12.0) (100)%
Animal Health (16.8) (2)% Anacin (1.2) (2)%
Alliance revenue 134.1 71% Other (33.2) (6)%
---------- ----------
Other (299.5) (4)%
---------- ----------
Total pharmaceuticals $943.9 9% Total consumer health care ($29.1) (1)%
========== ========== ========== ==========
2000 vs. 1999
Worldwide pharmaceutical net revenue increased 14% on an as-reported basis and
16% (primarily human pharmaceuticals) on a pro forma basis for 2000. Excluding
the negative impact of foreign exchange, pro forma worldwide pharmaceutical net
revenue increased 19% for 2000. Pro forma U.S. pharmaceutical net revenue
increased 22% for 2000 due primarily to higher sales of Prevnar (introduced in
the 2000 first quarter), Effexor XR (as a result of higher volume and market
share of new prescriptions, as well as expanded indications), Protonix
(introduced in the 2000 second quarter), Premarin products and animal health
products, and alliance revenue offset, in part, by lower sales of Lodine (due to
generic competition) and factor VIII.
Pro forma international pharmaceutical net revenue increased 7% for 2000 due
primarily to higher sales of Meningitec (introduced in the United Kingdom in the
1999 fourth quarter), Effexor XR (as a result of higher volume and market share
of new prescriptions, as well as expanded indications) and ReFacto (introduced
in the 1999 second quarter).
Worldwide consumer health care net revenue increased 4% on an as-reported and
pro forma basis for 2000. Excluding the negative impact of foreign exchange,
worldwide consumer health care net revenue increased 6% for 2000. U.S. consumer
health care net revenue increased 5% for 2000 due primarily to higher sales of
Centrum products (including Centrum Performance, which was launched in the
United States in the 1999 fourth quarter), cough/cold/allergy products, Chap
Stick and Flexagen (introduced in the United States in the 2000 second quarter).
International consumer health care net revenue increased 2% for 2000 due
primarily to higher sales of Centrum products and Caltrate offset, in part, by
lower sales of Anacin.
3
The following table sets forth the significant worldwide pharmaceutical and
consumer health care net revenue product fluctuations for the twelve months
ended December 31, 2000 compared with the same period in the prior year:
Pharmaceuticals Consumer Health Care
- -------------------------------------------- --------------------------------------------------
2000 vs. 1999 2000 vs. 1999
---------------------- ----------------------
($ millions) $ Increase % Increase ($ millions) $ Increase % Increase
Products (Decrease) (Decrease) Products (Decrease) (Decrease)
- -------------------- ---------- ---------- --------------------------- ---------- ----------
Prevnar $460.6 100% Centrum $24.4 5%
Effexor 378.3 48% Caltrate 15.1 12%
Protonix 145.0 100% Chap Stick 13.7 13%
Animal Health 133.6 20% Flexagen 11.8 100%
ReFacto 56.7 165% Advil (11.6) (2)%
Generics 14.4 3% Anacin (7.9) (9)%
Cordarone 10.9 6% Cough/cold/allergy products (6.7) (1)%
Alliance revenue 93.7 99% Other 56.9 12%
---------- ----------
Other 9.7 -
---------- ----------
Total pharmaceuticals $1,302.9 14% Total consumer health care $95.7 4%
========== ========== ========== ==========
The following table sets forth the percentage changes in 2001 as-reported and
2000 pro forma worldwide net revenue by operating segment and geographic area
compared with the prior year, including the effect volume, price and foreign
exchange had on these percentage changes:
% Increase (Decrease) % Increase (Decrease)
Years Ended December 31, 2001 Years Ended December 31, 2000 (1)(2)
----------------------------------------- -----------------------------------------
Foreign Total Net Foreign Total Net
Volume Price Exchange Revenue Volume Price Exchange Revenue
- -------------------------------------------------------------------------------------------------------------------
Pharmaceuticals
United States 10% 5% -- 15% 15% 7% -- 22%
International 4% 1% (6)% (1)% 14% -- (7)% 7%
----------------------------------------- -----------------------------------------
Total 8% 3% (2)% 9% 15% 4% (3)% 16%
========================================= =========================================
Consumer Health Care
United States (2)% 2% -- -- 4% 1% -- 5%
International (1)% 3% (5)% (3)% 4% 3% (5)% 2%
----------------------------------------- -----------------------------------------
Total (2)% 2% (1)% (1)% 4% 2% (2)% 4%
========================================= =========================================
Total
United States 8% 4% -- 12% 13% 5% -- 18%
International 4% 1% (6)% (1)% 12% 1% (7)% 6%
----------------------------------------- -----------------------------------------
Total 6% 3% (2)% 7% 13% 3% (3)% 13%
========================================= =========================================
(1) Effective January 1, 2000, the financial results of certain subsidiaries in
Japan and India, which previously were included on an equity basis, were
consolidated in the results of the Company. Also effective January 1, 2000,
the financial results of Immunex, which previously were consolidated in the
results of the Company, were deconsolidated and included on an equity
basis. Accordingly, alliance revenue was recorded in 2000 for co-promotion
agreements between the Company and Immunex. The 2000 pro forma net revenue
percentage changes reflect the respective consolidation and deconsolidation
of these subsidiaries and include alliance revenue from Immunex, assuming
all transactions occurred as of January 1, 1999. Neither the consolidation
nor the deconsolidation of these subsidiaries, nor the inclusion of
alliance revenue from Immunex, had any effect on income from continuing
operations in 2000.
(2) 2000 was restated to reflect the early adoption of new authoritative
accounting guidance as of January 1, 2001 reflecting certain rebates and
sales incentives (i.e., coupons and other rebate programs) as reductions of
revenues instead of selling and marketing expenses.
4
Operating Expenses
- ------------------
2001 vs. 2000
Cost of goods sold, as a percentage of Net revenue, decreased to 24.0% for 2001
compared with 24.7% for 2000. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2001 was 24.5%, a 0.6% decrease from 25.1% in
2000. The margin improvement resulted from a favorable mix of higher margin
products in both the pharmaceuticals and consumer health care segments and lower
royalty expenses offset, in part, by increased costs associated with improving
the U.S. production supply chain processes. Selling, general and administrative
expenses, as a percentage of Net revenue, decreased to 36.7% for 2001 compared
with 37.7% for 2000. The lower ratio of selling, general and administrative
expenses resulted from non-recurring launch expenses, primarily media, related
to pharmaceutical product launches in 2000, and lower co-promotion expenses for
Ziac, due to reduced sales as a result of generic competition. This ratio
improvement was partially offset by an increase in selling and marketing
expenses in the Company's animal health division to support the domestic launch
of ProHeart 6, a new single dose, canine heartworm preventative product.
Research and development expenses increased 11% for 2001 due primarily to
increased headcount and other research operating expenses, including higher
chemical and material costs, and ongoing clinical trials of pharmaceuticals in
several therapeutic categories. These increases were partially offset by lower
costs resulting from the timing of payments pursuant to certain pharmaceutical
collaborations and lower payments under licensing agreements. Pharmaceutical
research and development expenditures accounted for 96%, 96% and 95% of total
research and development expenditures in 2001, 2000 and 1999, respectively.
Pharmaceutical research and development expenses, as a percentage of worldwide
pharmaceutical net revenue, exclusive of infant nutritional sales and alliance
revenue, were 17%, 16% and 17% in 2001, 2000 and 1999, respectively.
2000 vs. 1999
Cost of goods sold, as a percentage of Net revenue, decreased to 24.7% for 2000
compared with 25.6% for 1999. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2000 was 25.1%, a 0.5% decrease from 1999. A
favorable mix of higher margin products in the pharmaceuticals segment was
offset, in part, by an increase in royalty expenses and costs associated with
improving the production and supply chain processes at certain international
sites.
Selling, general and administrative expenses, as a percentage of Net revenue,
increased to 37.7% for 2000 compared with 36.6% for 1999. Higher selling,
general and administrative expenses were due primarily to increased selling and
marketing expenses supporting higher field sales headcount and salaries,
promotional efforts for recent product launches and rapid growth products, and
direct-to-consumer programs. The increase in the ratio of these expenses, as a
percentage of Net revenue, was offset, in part, by deconsolidating Immunex in
2000 as these expenses carried a higher expense ratio and by consolidating Japan
and India in 2000 as their expense ratio was lower than the Company overall.
Research and development expenses increased 6% for 2000 due primarily to
certain advancements and ongoing clinical trials of pharmaceuticals in several
therapeutic categories, as well as additional payments for existing licensing
agreements offset, in part, by lower costs as a result of deconsolidating
Immunex in 2000.
Interest Expense and Other Income
- ---------------------------------
2001 vs. 2000
Interest expense, net increased substantially for 2001 due primarily to higher
weighted average debt outstanding, as compared with 2000. Weighted average debt
outstanding during 2001 and 2000 was $7,270.9 million and $3,853.0 million,
respectively. The increase in interest expense was partially offset by higher
capitalized interest resulting from additional capital projects, recognized
during 2001, and lower interest rates on outstanding commercial paper.
Other income, net increased 70% for 2001 due primarily to lower non-recurring
charges (as described below in the 2000 vs. 1999 Other income, net analysis),
higher gains on the sales of non-strategic assets and higher equity income.
5
2000 vs. 1999
Interest expense, net decreased 73% for 2000 due primarily to an increase in
interest income as a result of higher cash and cash equivalents, as well as
lower debt resulting from the payoff of the $1,000.0 million of 7.70% notes on
February 15, 2000. In addition, on June 30, 2000, the Company used a portion of
the proceeds from the sale of the Cyanamid Agricultural Products business to pay
down a substantial portion of the outstanding commercial paper borrowings.
Weighted average debt outstanding during 2000 and 1999 was $3,853.0 million and
$4,889.0 million, respectively.
Other income, net decreased 37% for 2000 due primarily to non-recurring
charges (including: payments for access to various pharmaceutical
collaborations, costs associated with a consent decree entered into with the FDA
in the 2000 third quarter (described below) and costs related to a product
discontinuation) and lower gains on the sales of non-strategic assets offset, in
part, by an insurance recovery of environmental costs, higher equity income and
lower Year 2000 conversion costs. In conjunction with the consent decree
identified above, the Company recorded a pre-tax charge of $56.1 million which
included payments to the U.S. government and charges associated with actions
required by the FDA based on an inspection of the Marietta, Pennsylvania and
Pearl River, New York facilities. Pursuant to the consent decree, the Company
will have a comprehensive inspection performed by expert consultants to
determine compliance with current Good Manufacturing Practices.
2001, 2000 and 1999 Unusual Transactions
- ----------------------------------------
During the 2001 third quarter, the Company recorded a charge of $950.0 million
($615.0 million after-tax or $0.46 per share-diluted) relating to the litigation
brought against the Company regarding the use of the diet drugs Pondimin (which
in combination with phentermine, a product that was not manufactured,
distributed or sold by the Company, was commonly referred to as "fen-phen") or
Redux. An initial litigation charge of $4,750.0 million ($3,287.5 million
after-tax or $2.51 per share-diluted) was recorded in the 1999 third quarter
followed by an additional litigation charge of $7,500.0 million ($5,375.0
million after-tax or $4.11 per share-diluted) recorded in the 2000 fourth
quarter. The combination of these three charges represents the estimated total
amount required to resolve all diet drug litigation, including all anticipated
funding requirements for the nationwide, class action settlement and costs to
resolve the claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right. Additionally, these charges
will cover any remaining administrative and legal expenses and costs associated
with the resolution of the claims of the initial opt outs and primary pulmonary
hypertension claimants (see Note 12 to the Consolidated Financial Statements and
the "Liquidity, Financial Condition and Capital Resources" section herein for
further discussion relating to the Company's additional financing requirements
for the future settlement payments).
During the 2000 first quarter, the Company and Warner-Lambert Company
terminated their merger agreement. The Company recorded income of $1,709.4
million ($1,111.1 million after-tax or $0.85 per share-diluted) in income from
continuing operations resulting from the receipt of a $1,800.0 million
termination fee provided for under the merger agreement offset, in part, by
certain related expenses (see Note 3 to the Consolidated Financial Statements).
In November 2000, the Company and Immunex completed a public equity offering
allowing the Company to sell 60.5 million shares of Immunex common stock.
Proceeds to the Company were $2,404.9 million, resulting in a gain on the sale
of $2,061.2 million ($1,414.9 million after-tax or $1.08 per share-diluted). The
Company used the net proceeds from the sale of its Immunex common stock to
reduce outstanding commercial paper and for other general corporate purposes
(see Note 2 to the Consolidated Financial Statements).
6
In November 2000, in accordance with an FDA request, the Company immediately
ceased global production and shipments of any products containing PPA and
voluntarily withdrew any such products from customer warehouses and retail store
shelves. As a result, the Company recorded a special charge of $80.0 million
($52.0 million after-tax or $0.04 per share-diluted) to provide primarily for
product returns and the write-off of inventory (see Note 3 to the Consolidated
Financial Statements).
During the 2000 fourth quarter, the Company recorded a special charge of
$267.0 million ($173.0 million after-tax or $0.13 per share-diluted) related to
the discontinuation of certain products. The special charge provided for fixed
asset impairments, inventory write-offs, severance obligations, idle plant costs
and contract termination costs (see Note 3 to the Consolidated Financial
Statements).
At December 31, 2000, the Company performed goodwill and other intangible
reviews and noted that projected profitability and future cash flows associated
with generic pharmaceuticals and the Solgar consumer health care product line
would not be sufficient to recover the remaining goodwill related to these
product lines. As a result, the Company recorded a charge of $401.0 million
($341.0 million after-tax or $0.26 per share-diluted) to write down the carrying
value of goodwill related to these product lines, to fair value, representing
discounted future cash flows (see Note 3 to the Consolidated Financial
Statements).
During the 1999 second quarter, the Company recorded a special charge
aggregating $82.0 million ($53.0 million after-tax or $0.04 per share-diluted)
for estimated costs associated with the suspension of shipments and the
voluntary market withdrawal of RotaShield, the Company's rotavirus vaccine (see
Note 3 to the Consolidated Financial Statements).
Income (Loss) from Continuing Operations before Taxes
- -----------------------------------------------------
The following table sets forth worldwide income (loss) from continuing
operations before taxes by operating segment together with the percentage
changes from the comparable periods in the prior year on an as-reported basis:
2001 vs. 2000 2000 vs. 1999
(Dollar amounts in millions) Years Ended December 31, ------------- -------------
Income (Loss) from Continuing ------------------------------------- % Increase % Increase
Operations before Taxes(1) 2001 2000 1999 (Decrease) (Decrease)
- -------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $ 3,503.5 $ 2,919.5 $ 2,538.6 20% 15%
Consumer Health Care 592.1 626.6 594.6 (6)% 5%
---------------------------------------- ---------------------------
4,095.6 3,546.1 3,133.2 15% 13%
Corporate(2) (1,226.9) (4,647.1) (5,040.5) (74)% (8)%
---------------------------------------- ---------------------------
Total(3) $ 2,868.7 $(1,101.0) $(1,907.3) -- (42)%
======================================== ===========================
(1) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001, 2000 and 1999 as follows: Pharmaceuticals--$136.8,
$147.8 and $154.3 and Consumer Health Care--$23.7, $31.8 and $32.7,
respectively.
(2) 2001, 2000 and 1999 Corporate included litigation charges of $950.0,
$7,500.0 and $4,750.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drugs Redux or Pondimin.
The charges provide for all anticipated payments in connection with the
nationwide, class action settlement, anticipated costs to resolve the
claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right, costs to resolve the
claims of PPH claimants and initial opt out claimants, and administrative
and litigation expenses, net of insurance.
2000 Corporate also included:
o Income of $1,709.4 resulting from the receipt of a $1,800.0 termination
fee provided for under the merger agreement with Warner-Lambert Company
offset, in part, by certain related expenses.
7
o Income of $2,061.2 related to the Company selling a portion of its
investment in Immunex common stock in a public equity offering with
Immunex.
o Goodwill impairment of $401.0 related to the goodwill associated with
generic pharmaceuticals and the Solgar consumer health care product line.
o A special charge of $80.0 related to the voluntary ceasing of
production and subsequent market withdrawal of products containing PPA.
o A special charge of $267.0 related to costs associated with certain
product discontinuations.
1999 Corporate also included a special charge of $82.0 related to the
suspension of shipments and the voluntary market withdrawal of RotaShield,
the Company's rotavirus vaccine.
Excluding the 2001, 2000 and 1999 litigation charges, 2000 termination fee,
2000 gain on the sale of Immunex common stock, 2000 goodwill impairment,
and 2000 and 1999 special charges, Corporate expenses, net increased 63%
for 2001 and decreased 19% for 2000.
(3) Excluding the 2001, 2000 and 1999 litigation charges, 2000 termination fee,
2000 gain on the sale of Immunex common stock, 2000 goodwill impairment,
and 2000 and 1999 special charges, total income from continuing operations
before taxes increased 13% for 2001 and 15% for 2000.
The following explanations of changes in income (loss) from continuing
operations before taxes, by operating segment, for 2001 compared with 2000, and
2000 compared with 1999, exclude items listed in footnote (2) to the table
above:
Pharmaceuticals
Worldwide pharmaceutical income from continuing operations before taxes
increased 20% (22% for human pharmaceuticals) for 2001 due primarily to higher
U.S. net revenue (favorable product mix) and other income, net (primarily lower
non-recurring charges and higher gains on asset sales) offset, in part, by
higher selling, general and administrative expenses and research and development
expenses. Higher selling, general and administrative expenses were due primarily
to increased promotional expenses to support existing product lines and sales
force expansion offset, in part, by a decrease in marketing expenses related to
product launches that occurred in 2000.
Worldwide pharmaceutical income from continuing operations before taxes
increased 15% (11% for human pharmaceuticals) for 2000 due primarily to higher
worldwide net revenue (including alliance revenue) offset, in part, by higher
selling, general and administrative expenses, research and development expenses,
and other expenses (primarily non-recurring charges). Higher selling, general
and administrative expenses were due primarily to increased media and
promotional expenses to support product launches and existing product lines
through increased headcount.
Consumer Health Care
Worldwide consumer health care income from continuing operations before taxes
decreased 6% for 2001 due primarily to lower worldwide sales and lower other
income, net (primarily lower gains on sales of non-strategic assets). Worldwide
consumer health care income from continuing operations before taxes increased 5%
for 2000 due primarily to higher worldwide sales.
Corporate
Corporate expenses, net increased 63% for 2001 due primarily to higher interest
expense, net and lower other income related to an insurance recovery of
environmental costs recorded in 2000 offset, in part, by lower general and
administrative expenses. Corporate expenses, net decreased 19% for 2000 due
primarily to lower interest expense, net and current year insurance recoveries
related to environmental costs offset, in part, by lower gains on sales of
non-strategic assets, higher general and administrative expenses, and costs
related to a product discontinuation.
8
Effective Tax Rate
- ------------------
The effective tax rate for 2001 was 24.1% compared with 25.5% for 2000 and 27.1%
for 1999. The downward trend in the effective tax rates was due primarily to an
increased benefit from manufacturing in lower taxed jurisdictions and higher
research credits.
Income (Loss) and Diluted Earnings (Loss) per Share from Continuing Operations
- ------------------------------------------------------------------------------
Income and diluted earnings per share from continuing operations in 2001 were
$2,285.3 million and $1.72, respectively, compared with a loss and diluted loss
per share from continuing operations of $901.0 million and $0.69 in 2000,
respectively. Loss and diluted loss per share from continuing operations in 1999
were $1,207.2 million and $0.92, respectively. The income (loss) from continuing
operations for 2001, 2000 and 1999 included the following unusual items:
Income (Loss) Diluted Earnings (Loss) per Share
from Continuing Operations Share from Continung Operations
(In millions, except per share amounts) ------------------------------------- ---------------------------------
Years Ended December 31, 2001 2000 1999 2001 2000 1999
- -------------------------------------------------------------------------------- ---------------------------------
Income from continuing operations
before unusual items and
including the dilutive effect of
common stock equivalents (CSE) $ 2,900.3 $2,514.0 $ 2,133.3 $ 2.18 $ 1.90 $ 1.61
Dilutive effect of CSE * -- -- -- -- 0.02 0.02
------------------------------------- ---------------------------------
$ 2,900.3 $2,514.0 $ 2,133.3 $ 2.18 $ 1.92 $ 1.63
Warner-Lambert Company
termination fee -- 1,111.1 -- -- 0.85 --
Gain on sale of Immunex
common stock -- 1,414.9 -- -- 1.08 --
Redux and Pondimin diet drug
litigation charges (615.0) (5,375.0) (3,287.5) (0.46) (4.11) (2.51)
Goodwill impairment -- (341.0) -- -- (0.26) --
Special charges:
Voluntary market withdrawals -- (52.0) (53.0) -- (0.04) (0.04)
Product discontinuations -- (173.0) -- -- (0.13) --
------------------------------------- ---------------------------------
Income (loss) from continuing
operations $ 2,285.3 $ (901.0) $ (1,207.2) $ 1.72 $ (0.69) $ (0.92)
===================================== =================================
* The $0.02 per share benefit represents the impact on income from continuing
operations of excluding the dilutive effect of CSE. 2001 diluted earnings
per share from continuing operations of $2.18 includes the dilutive impact
of CSE.
For further details related to the items listed in the table above, refer to
the discussion of "2001, 2000 and 1999 Unusual Transactions" herein.
Excluding all unusual items from the 2001 and 2000 results listed in the
table above and including the $0.02 per share dilutive effect of common stock
equivalents in the 2000 results, both income and diluted earnings per share from
continuing operations in 2001 increased 15% compared with 2000. The increases
were due primarily to higher U.S. pharmaceutical net revenue and higher other
income, net offset, in part, by higher selling, general and administrative
expenses, research and development expenses, and interest expense, net.
Excluding all unusual items from the 2000 and 1999 results listed in the
table above and including the $0.02 per share dilutive effect of common stock
equivalents in 2000 and 1999 results, both income and
9
diluted earnings per share from continuing operations in 2000 increased 18%
compared with 1999. The increases were due primarily to higher worldwide sales
of pharmaceuticals and lower interest expense, net offset, in part, by higher
selling, general and administrative expenses and research and development
expenses.
Discontinued Operations
- -----------------------
On June 30, 2000, the Company announced that it had completed the sale of the
Cyanamid Agricultural Products business to BASF. Under the terms of the
definitive agreement, BASF paid the Company $3,800.0 million in cash and assumed
certain debt. As a result, the Company recorded an after-tax loss on the sale of
this business of $1,573.0 million or $1.20 per share-diluted and reflected this
business as a discontinued operation beginning in the 2000 first quarter and
restated all prior periods presented (see Note 2 to the Consolidated Financial
Statements).
Liquidity, Financial Condition and Capital Resources
Cash and cash equivalents decreased $899.6 million, while total debt increased
by $7,001.1 million in 2001. The activity of these cash flows during 2001
related primarily to the following items:
o Payments of $7,257.9 million related to the Pondimin (which in combination
with phentermine, a product that was not manufactured, distributed or sold
by the Company, was commonly referred to as "fen-phen") and Redux
litigation. These payments were financed primarily from borrowing
activities. As discussed in Note 12 to the Consolidated Financial
Statements, during 1999, the Company announced a nationwide, class action
settlement to resolve litigation brought against the Company regarding the
use of the diet drugs Redux or Pondimin. Payments to provide settlement
benefits, if needed, may continue for approximately 16 years after final
judicial approval. Payments made to date and future payments related to the
diet drug litigation are anticipated to be financed through existing cash
resources, cash flows from operating activities, additional commercial
paper borrowings, as well as term debt financings and international
earnings remitted back to the United States, if necessary.
o Capital expenditures of $1,924.3 million due primarily to new production
capacity expansion worldwide, including biotechnology facilities, research
and development facilities, and to improve compliance of U.S. supply chain
processes. A similar level of capital expenditures is expected to continue
in 2002.
o Dividends totaling $1,211.1 million consisting primarily of the Company's
annual common stock dividend of $0.92 per share that provided the Company's
stockholders with an approximate yield of 1.5%.
o Net marketable security purchases, throughout 2001, of $941.0 million to
support an effective cash management strategy.
o Contributions to fund the Company's defined benefit pension plans totaling
$429.7 million.
o An increase in other current assets, excluding deferred taxes, of $395.8
million primarily for anticipated tax refunds.
o An increase in inventories of $273.1 million primarily related to planning
for expected product demand.
10
These cash uses were partially offset by other net cash generated by
operations of $3,909.6 million, proceeds from sales of assets of $408.2 million,
proceeds from the exercise of stock options of $224.6 million and the proceeds
from borrowing activities identified above.
Additional Liquidity, Financial Condition and Capital Resource Information
At December 31, 2001, the carrying value of cash equivalents approximated fair
value due to the short-term, highly liquid nature of cash equivalents, which
have original maturities of three months or less. Interest rate fluctuations
would not have a significant effect on the fair value of cash equivalents held
by the Company.
The Company maintains a $2,000.0 million credit facility, which supports
borrowings under the commercial paper program and terminates on July 31, 2002.
Since the $2,000.0 million credit facility terminates in less than one year,
commercial paper outstanding of $1,817.2 million, supported by this facility,
was classified as current debt in Loans payable as of December 31, 2001. In
March 2001, the Company obtained an additional revolving credit facility of
$3,000.0 million to support its commercial paper program. The Company offers its
commercial paper in a very liquid market commensurate with its short-term credit
ratings from Moody's (P2), S&P (A1) and Fitch (F1). In March 2002, the Company
renewed the $3,000.0 million credit facility for an additional 364-day term, and
reduced the $2,000.0 million credit facility to $1,000.0 million until it
matures on July 31, 2002.
In March 2001, the Company issued three tranches of Notes in a transaction
exempt from registration under the Securities Act, pursuant to Rule 144A, as
follows:
o $500.0 million 5.875% Notes due March 15, 2004
o $1,000.0 million 6.25% Notes due March 15, 2006
o $1,500.0 million 6.70% Notes due March 15, 2011
The interest rate payable on each series of Notes is subject to an increase
of 0.25 percentage points per level of downgrade in the Company's credit rating
by Moody's or S&P. However, the total adjustment to the interest rate for the
series of Notes cannot exceed two percentage points. There is no adjustment to
the interest rate payable on each series of Notes for the first single level
downgrade in the Company's credit rating by S&P. In the case of the $1,500.0
million 6.70% Notes, the interest rate in effect on March 15, 2006 for such
Notes will, thereafter, become the effective interest rate until maturity on
March 15, 2011. The Company would incur a total of approximately $7.5 million of
additional annual interest expense for every 0.25 percentage point increase in
the interest rate. If Moody's or S&P subsequently were to increase the Company's
credit rating, the interest rate payable on each series of Notes would be
subject to a decrease of 0.25 percentage points for each level of credit rating
increase. The interest rate payable for the series of Notes cannot be reduced
below the original coupon rate of each series of Notes.
In addition to the Notes issued in March 2001, the Company has outstanding:
$250.0 million 6.50% Notes due October 2002, $1,000.0 million 7.90% Notes due
February 2005 and $250.0 million 7.25% debentures due March 2023.
The Company has a common stock repurchase program under which the Company is
authorized, at December 31, 2001, to repurchase 6,492,460 additional shares in
the future. Depending upon market conditions, among other things, the Company
may make limited repurchases of its common stock to offset stock issuances in
connection with exercises of stock options during 2002.
Management remains confident that cash flows from operating activities and
available financing resources will be adequate to fund the Company's operations,
pay all amounts related to the Redux and Pondimin diet drug litigation, pay
dividends, maintain the ongoing programs of capital expenditures, including the
amount already committed at December 31, 2001 of $851.6 million, and repay both
11
the principal and interest on its outstanding obligations, without requiring the
disposition of any significant strategic core assets or businesses.
Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk from changes in foreign currency exchange
rates and interest rates that could impact its financial position, results of
operations and cash flows. The Company manages its exposure to these market
risks through its regular operating and financing activities and, when deemed
appropriate, through the use of derivative financial instruments. The Company
uses derivative financial instruments as risk management tools and not for
trading purposes. In addition, derivative financial instruments are entered into
with a diversified group of major financial institutions in order to manage the
Company's exposure to non-performance on such instruments.
Foreign Currency Risk Management: The Company generates a portion of Net
revenue from sales to customers located outside the United States, principally
in Europe. International sales are generated mostly from international
subsidiaries in the local countries with the sales typically denominated in the
local currency of the respective country. These subsidiaries also incur most of
their expenses in the local currency. Accordingly, most international
subsidiaries use the local currency as their functional currency. International
business, by its nature, is subject to risks including, but not limited to:
differing economic conditions, changes in political climate, differing tax
structures, other regulations and restrictions, and foreign exchange rate
volatility. Accordingly, future results could be adversely impacted by changes
in these or other factors.
The Company has established programs to protect against adverse changes in
exchange rates due to foreign currency volatility. The Company believes that the
foreign currency risks to which it is exposed are not reasonably likely to have
a material adverse effect on the Company's financial position, results of
operations or cash flows due to the high concentration of sales in the United
States. No single foreign currency accounted for 5% or more of 2001 or 2000
worldwide net revenue, except for the British pound sterling, which accounted
for 5% and 7% of 2001 and 2000 worldwide net revenue, respectively. On January
1, 2002, 12 member countries of the European Union adopted the Euro as a new
common legal currency. Collectively, these countries accounted for 11% of both
2001 and 2000 worldwide Net revenue.
Interest Rate Risk Management: The fair value of the Company's fixed-rate
long-term debt is sensitive to changes in interest rates. Interest rate changes
result in gains/losses in the market value of this debt due to differences
between the market interest rates and rates at the inception of the debt
obligation. The Company manages this exposure to interest rate changes primarily
through the use of interest rate swaps. The Company has swapped an appropriate
amount of its fixed rate debt into variable rate debt to maintain a
fixed-to-variable ratio of approximately 1 to 1 on its total debt position,
consistent with the Company's debt management philosophy.
12
At December 31, 2001, the notional/contract amounts, carrying values and fair
values of the Company's financial instruments were as follows:
(Dollar amounts in millions) Notional/
Description Contract Amount Carrying Value Fair Value
- --------------------------------------------------------------------------------
Forward contracts (1) $438.8 $17.9 $17.9
Option contracts (1) 796.4 12.9 12.9
Interest rate swaps 1,500.0 12.8 12.8
Outstanding debt (2) 9,445.5 9,454.6 9,607.7
(1) If the value of the U.S. dollar were to increase or decrease by 10%, in
relation to all hedged foreign currencies, the net receivable on the
forward and option contracts would decrease or increase by approximately
$68.6.
(2) If the interest rates were to increase or decrease by one percentage point,
the fair value of the outstanding debt would increase or decrease by
approximately $215.1.
The estimated fair values approximate amounts at which these financial
instruments could be exchanged in a current transaction between willing parties.
Therefore, fair values are based on estimates using present value and other
valuation techniques that are significantly affected by the assumptions used
concerning the amount and timing of estimated future cash flows and discount
rates that reflect varying degrees of risk. Specifically, the fair value of
forward contracts and interest rate swaps reflects the present value of the
future potential gain if settlement were to take place on December 31, 2001; the
fair value of option contracts reflects the present value of future cash flows
if the contracts were settled on December 31, 2001; and the fair value of
outstanding debt instruments reflects a current yield valuation based on
observed market prices as of December 31, 2001.
Forward-Looking Information and Factors That May Affect Future Results
This Annual Report, including management's discussion and analysis set forth
herein, contains certain forward-looking statements, including, among other
things, statements regarding the Company's results of operations, future impact
of presently known trends, Euro currency, competition, liquidity, financial
condition and capital resources, Premarin, Enbrel supply, Meningitec sales,
foreign currency and interest rate risk, the nationwide, class action settlement
relating to Redux and Pondimin, and additional litigation charges related to
Redux and Pondimin including those for opt outs. These forward-looking
statements are based on current expectations of future events that involve risks
and uncertainties, including, without limitation, risks associated with the
inherent uncertainty of pharmaceutical research, product development,
manufacturing and commercialization, and economic conditions, including interest
and currency exchange rate fluctuations, the impact of competitive or generic
products, product liability and other types of lawsuits, the impact of
legislative and regulatory compliance and product approval obtainment, and
patents. From time to time, we also may provide oral or written forward-looking
statements in other materials we release to the public. However, the Company
assumes no obligation to publicly update any forward-looking statements, whether
as a result of new information, future events or otherwise. Certain additional
factors which could cause the Company's actual results to differ materially from
expected and historical results have been identified by the Company in Exhibit
99 to the Company's 2000 Annual Report on Form 10-K, and the Company's 2001
Annual Report on Form 10-K, which will be filed by April 1, 2002, as well as the
sections identified below.
13
Future Impact of Presently Known Trends
- ---------------------------------------
Pension Assets and Other Postretirement Plan Assumptions
As a result of the recent retraction in the global equity markets, the Company
has experienced a significant reduction in the market value of assets held by
the Company's pension plan. The Company's pension plan assets also were
decreased by the normal annual benefit payments, which historically have been
offset by the positive actual return on plan assets. In order to mitigate the
decline, the Company made a $400.0 million funding contribution to the U.S.
Non-bargaining pension plan in December 2001. Despite the contribution, the
market value decline is expected to negatively impact pension expense in 2002.
In addition, based on an annual internal study of actuarial assumptions, the
expected long-term rate of return on plan assets and discount rate both have
been decreased by 25 basis points to 9.25% and 7.25%, respectively. As a result
of these developments, the 2002 net periodic benefit cost for pensions is
anticipated to be approximately $40.0 million to $50.0 million higher than in
2001. The Company also has reviewed the principal actuarial assumptions relating
to its other postretirement plan. In response to the recent increase in health
care costs in the United States, the Company has increased the health care cost
trend rate to 9.5% for 2001, decreasing to 5.0% by 2005. In reviewing
postretirement claims data and other related assumptions, the Company believes
that this trend rate increase appropriately reflects the trend aspects of the
Company's postretirement plan as of December 31, 2001. As a result of the
increase in the health care cost trend rate, the 2002 net periodic benefit cost
for other postretirement benefits is anticipated to be approximately $10.0
million to $20.0 million higher than in 2001.
Proposed Acquisition of Immunex by Amgen
In December 2001, Amgen Inc. and Immunex signed a definitive agreement providing
for Amgen to acquire Immunex in a merger transaction. The terms of the agreement
require that each share of Immunex common stock be exchanged for 0.44 shares of
Amgen common stock and $4.50 in cash. Upon completion of the merger transaction,
the Company would receive over $1,000.0 million in cash proceeds, based upon the
number of shares the Company owned of Immunex as of December 31, 2001. The
Company may use these cash proceeds to repay outstanding debt obligations, fund
ongoing programs of capital expenditures or fund other working capital
requirements.
Potential Tax Refund
On October 5, 2001, the U.S. District Court for the District of Columbia entered
judgment in favor of the Company in Boca Investerings Partnership v. U.S., in
which the Company challenged the disallowance by the Internal Revenue Service
(IRS) of a capital loss deduction in 1990 related to a partnership investment.
The Court ordered the IRS to refund the tax paid, approximately $226.0 million,
together with interest. The IRS has appealed the decision and, as a result, the
Company has not recognized this anticipated refund in its 2001 Consolidated
Financial Statements.
Impact of Recently Issued Accounting Standards
As of January 1, 2002, the Company adopted SFAS No. 142, Goodwill and Other
Intangible Assets, which requires, among other things, the ceasing of
amortization of goodwill and certain indefinite lived intangibles. In accordance
with the adoption of SFAS No. 142, the Company will cease amortizing goodwill.
Included in Selling, general and administrative expenses for 2001 was
approximately $160.5 million ($153.9 million after-tax or $0.12 per
share-diluted) of goodwill amortization. The Company currently is assessing the
impact the new impairment testing requirements may have on its financial
position, results of operations and cash flows.
In April 2001, the EITF reached a consensus on Issue No. 00-25, Vendor Income
Statement Characterization of Consideration Paid to a Reseller of the Vendor's
Products. EITF No. 00-25 requires the cost of certain vendor considerations be
classified as a reduction of revenue rather than a marketing expense. The
Company will adopt the provisions of EITF No. 00-25 effective January 1, 2002.
The adoption of EITF No. 00-25 will result in reclassifications of certain
marketing expenses to revenues and will have no effect on income from continuing
operations. The Company does not anticipate the adoption of this consensus to
significantly affect the growth rate of net revenues.
14
Critical Accounting Policies
The Company does not consider any specific accounting policies to be critical to
the economic success of the entity. The Company does not participate in, nor has
created, any off-balance sheet financing or other off-balance sheet special
purpose entities, other than operating leases. In addition, the Company does not
enter into any derivative financial instruments for trading purposes and uses
derivative financial instruments solely for managing its exposure to certain
market risks from changes in foreign currency exchange rates and interest rates.
Euro Currency
- -------------
On January 1, 2002, Euro banknotes and coins were introduced in 12 of the 15
member states of the European Union. The new common legal currency replaces the
individual national currencies that currently are being withdrawn. The Company
has effectively converted to the new single currency by identifying critical
areas affected by the change and by successfully implementing programs to
facilitate transition. The costs related to the Euro conversion and transition
period did not have a material adverse effect on the Company's financial
position, results of operations or cash flows.
Competition
- -----------
The Company operates in the highly competitive pharmaceutical and consumer
health care industries. The Company is not dependent on any one patent-protected
product or line of products for a substantial portion of its net revenues or
results of operations. Premarin, the Company's principal conjugated estrogens
product manufactured from pregnant mare's urine, and related products Prempro
and Premphase (which are single tablet combinations of the conjugated estrogens
in Premarin and the progestin medroxyprogesterone acetate), are the leaders in
their categories and contribute significantly to net revenue and results of
operations. Premarin's natural composition is not subject to patent protection
(although Prempro has patent protection). The principal uses of Premarin,
Prempro and Premphase are to manage the symptoms of menopause and to prevent
osteoporosis, a condition involving a loss of bone mass in postmenopausal women.
Estrogen-containing products manufactured by other companies have been marketed
for many years for the treatment of menopausal symptoms, and several of these
products also have an approved indication for the prevention of osteoporosis.
During the past several years, other manufacturers have introduced products for
the treatment and/or prevention of osteoporosis. New products containing
different estrogens than those found in Prempro and Premphase and having many
forms of the same indications also have been introduced. Some companies have
attempted to obtain approval for generic versions of Premarin. These products,
if approved, would be routinely substitutable for Premarin and related products
under many state laws and third-party insurance payer plans. In May 1997, the
FDA announced that it would not approve certain synthetic estrogen products as
generic equivalents of Premarin given known compositional differences between
the active ingredient of these products and Premarin. Although the FDA has not
approved any generic equivalent to Premarin to date, Premarin will continue to
be subject to competition from existing and new competing estrogen and other
products for its approved indications and may be subject to generic competition
from either synthetic or natural conjugated estrogens products in the future. At
least one other company has announced that it is in the process of developing a
generic version of Premarin from the same natural source, and the Company
currently cannot predict the timing or outcome of these or any other efforts.
15
The Company has been experiencing inconsistent results on dissolution testing
of certain dosage strengths of Premarin and is working with the FDA to resolve
this issue. Until this issue is resolved, supply shortages of one or more dosage
strengths may occur. Although these shortages may adversely affect Premarin
sales in one or more accounting periods, the Company believes that, as a result
of current adequate inventory levels and the Company's enhanced process
controls, testing protocols and an ongoing formulation improvement project,
overall Premarin family sales will not be significantly impacted.
Enbrel Supply
- -------------
Although the market demand for Enbrel is increasing, the sales growth currently
is constrained by limits on the existing source of supply. This is expected to
continue until the retrofitting of a Rhode Island facility is completed and
approved, which is expected to occur in 2002. If the market demand continues to
grow, there may be further supply constraints even after the Rhode Island
facility begins producing Enbrel. The current plan for the longer term includes
a new manufacturing facility, which is being constructed in Ireland.
16
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The financial statements and supplementary data required to be presented in Item
8 of this Annual Report on Form 10-K/A are included in Part IV of this report.
PART IV
-------
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a)1. Financial Statements
--------------------
The following Consolidated Financial Statements, Notes to
Consolidated Financial Statements and Reports of Independent
Public Accountants are included in Part IV of this report:
Pages
Consolidated Balance Sheets as
of December 31, 2001 and 2000 25
Consolidated Statements of Operations
for the years ended December 31,
2001, 2000 and 1999 26
Consolidated Statements of Changes in
Stockholders' Equity for the years ended
December 31, 2001, 2000 and 1999 27
Consolidated Statements of Cash Flows
for the years ended December 31, 2001
2000 and 1999 28
Notes to Consolidated Financial Statements 29-62
Reports of Independent Accountants 63-64
Quarterly Financial Data (Unaudited) 65
(a)2. Financial Statement Schedule
-----------------------------
The following consolidated financial information is included in
Part IV of this report:
Pages
-----
Reports of Independent Accountants on
Supplemental Schedule 66
Schedule II - Valuation and Qualifying Accounts
for the years ended December 31, 2001,
2000 and 1999 67
Schedules other than that listed above are omitted because they
are not applicable.
17
(a)3. Exhibits
--------
Exhibit No. Description
----------- -----------
(3.1)+ The Company's Restated Certificate of Incorporation as amended to
date.
(3.2)+ The Company's By-Laws as amended to date.
(4.1) Indenture, dated as of April 10, 1992, between the Company and The
Chase Manhattan Bank (successor to Chemical Bank), as Trustee, is
incorporated by reference to Exhibit 2 of the Company's Form 8-A
dated August 25, 1992 (File 1-1225).
(4.2) Supplemental Indenture, dated October 13, 1992, between the
Company and The Chase Manhattan Bank (successor to Chemical
Bank), as Trustee, is incorporated by reference to the Company's
Form 10-Q for the quarter ended September 30, 1992 (File 1-1225).
(4.3) Amended and Restated Rights Agreement, dated as of January 8,
2002, by and between the Company and The Bank of New York, as
Rights Agent, with the form of Certificate of Designation attached
as Exhibit A thereto and the form of Right Certificate attached as
Exhibit B thereto is incorporated herein by reference to Exhibit
4.1 of the Company's Form 8-A/A, Amendment No. 2, dated January 8,
2002.
(4.4) Certificate of Designation of Series A Junior Participating
Preferred Stock of the Company is incorporated herein by reference
to Exhibit 4.2 of the Company's Form 8-A, dated October 14, 1999.
(10.1) Purchase Agreement, by and among American Cyanamid Company,
American Home Products Corporation and BASF Aktiengesellschaft,
dated as of March 20, 2000 is incorporated by reference to Exhibit
10.1 to the Company's Quarterly Report on Form 10-Q for the period
ended March 31, 2000 (Confidential Treatment Requested -
confidential portions have been omitted and filed separately with
the Commission).
(10.2) First Amendment to the Purchase Agreement, by and among
American Cyanamid Company, American Home Products Corporation,
and BASF Aktiengesellschaft dated as of June 30, 2000 is
incorporated by reference to Exhibit 10.2 to the Company's
Current Report on Form 8-K filed on July 17, 2000 (Confidential
Treatment Requested - confidential portions have been omitted and
filed separately with the Commission).
(10.3) Second Supplemental Indenture, dated as of March 30, 2001, between
the Corporation and The Chase Manhattan Bank (as successor to
Manufacturers Hanover Trust Company) is incorporated by reference
to Exhibit 4.3 of the Registration Statement of Form S-4 of the
Company filed on April 27, 2001.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
18
(10.4) Exchange and Registration Rights Agreement, dated March 30,
2001, among the Company and Chase Securities Inc., Salomon Smith
Barney Inc., as Representatives of the several Initial
Purchasers, is incorporated by reference to Exhibit 4.4 of the
Registration Statement on Form S-4 of the Company filed on April
27, 2001.
(10.5) Second Amendment to the Purchase Agreement, by and among American
Cyanamid Company, American Home Products Corporation, and BASF
Aktiengesellschaft dated as of December 9, 2000 (Confidential
Treatment Requested - confidential portions have been omitted and
filed separately with the Commission).
(10.6) B Credit Agreement, dated as of September 9, 1994, among the
Company, American Home Food Products, Inc., Sherwood Medical
Company, A.H. Robins Company, Incorporated, the several banks and
other financial institutions from time to time parties thereto
and The Chase Manhattan Bank (successor to Chemical Bank), as
agent for the lenders thereunder, filed as Exhibit 11(b)(3) to
Amendment No. 7 to the Schedule 14D-1, dated September 22, 1994
(File 1-1225), is incorporated herein by reference.
(10.7) First Amendment to B Credit Agreement, dated as of August 4,
1995, among the Company, American Home Food Products, Inc.,
Sherwood Medical Company, A.H. Robins Company, Incorporated, the
several banks and other financial institutions from time to time
parties thereto and The Chase Manhattan Bank (successor to
Chemical Bank), as agent for the lenders thereunder, is
incorporated by reference to Exhibit 10.4 of the Company's Form
10-K for the year ended December 31, 1995 (File 1-1225).
(10.8) Second Amendment to B Credit Agreement, dated as of August 2,
1996, among the Company, American Home Food Products, Inc.,
Sherwood Medical Company, A.H. Robins Company, Incorporated, the
several banks and other financial institutions from time to time
parties thereto and The Chase Manhattan Bank (successor to
Chemical Bank), as agent for the lenders thereunder, is
incorporated by reference to Exhibit 10.6 of the Company's Form
10-K for the year ended December 31, 1996 (File 1-1225).
(10.9) Third Amendment to B Credit Agreement, dated as of July 31,
1997, among the Company, Sherwood Medical Company, A.H. Robins
Company, Incorporated, AC Acquisition Holding Company, the
several banks and other financial institutions from time to time
parties thereto and The Chase Manhattan Bank (successor to
Chemical Bank), as agent for the lenders thereunder, is
incorporated by reference to Exhibit 10.8 of the Company's Form
10-K for the year ended December 31, 1997.
(10.10) Letter, dated March 26, 1998, amending the B Credit Agreement,
among the Company, AC Acquisition Holding Company, A.H. Robins
Company, Incorporated, the lender parties thereto and The Chase
Manhattan Bank (successor to Chemical Bank), as Agent, dated as
of September 9, 1994 and as amended is incorporated herein by
reference to Exhibit 10.1 of the Company's Form 10-Q for the
quarter ended March 31, 1998.
19
(10.11) Credit Agreement, dated as of March 5, 2001, among the
Company, the banks and other financial institutions from time to
time parties thereto and The Chase Manhattan Bank, as
administrative agent for the lenders thereto is incorporated
herein by reference to Exhibit 10.9 of the Company's 10-K for the
year ended December 31, 2000.
(10.12)+ Credit Agreement, dated as of March 4, 2002, among the Company,
the banks and other financial institutions from time to time
parties thereto and JPMorgan Chase Bank, as administrative agent
for the lenders thereto.
(10.13)* 1985 Stock Option Plan, as amended, is incorporated by reference
to Exhibit 10.4 of the Company's Form 10-K for the year ended
December 31, 1991 (File 1-1225).
(10.14)* Amendment to the 1985 Stock Option Plan is incorporated by
reference to Exhibit 10.9 of the Company's Form 10-K for the year
ended December 31, 1995 (File 1-1225).
(10.15)* Amendment to the 1985 Stock Option Plan is incorporated by
reference to Exhibit 10.12 of the Company's Form 10-K for the
year ended December 31, 1996 (File 1-1225).
(10.16)* 1990 Stock Incentive Plan is incorporated by reference to
Exhibit 28 of the Company's Form S-8 Registration Statement File
No. 33-41434 under the Securities and Exchange Act of 1933, filed
June 28, 1991 (File 1-1225).
(10.17)* Amendment to the 1990 Stock Incentive Plan is incorporated by
reference to Exhibit 10.13 of the Company's Form 10-K for the
year ended December 31, 1995 (File 1-1225).
(10.18)* Amendment to the 1990 Stock Incentive Plan is incorporated by
reference to Exhibit 10.21 of the Company's Form 10-K for the
year ended December 31, 1996 (File 1-1225).
(10.19)*+ Amendment to 1990 Stock Incentive Plan.
(10.20)* 1993 Stock Incentive Plan, as amended to date, is incorporated
by reference to Appendix III of the Company's definitive Proxy
Statement filed March 18, 1999.
(10.21)*+ Amendment to 1993 Stock Incentive Plan.
(10.22)* 1996 Stock Incentive Plan, as amended to date, is incorporated
by reference to Appendix II of the Company's definitive Proxy
Statement filed March 18, 1999.
(10.23)*+ Amendment to 1996 Stock Incentive Plan.
(10.24)* 1999 Stock Incentive Plan is incorporated by reference to
Appendix I of the Company's definitive Proxy Statement filed
March 18, 1999.
*Denotes management contract or compensatory plan or arrangement required
to be filed as an exhibit hereto.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
20
(10.25)*+ Amendment to 1999 Stock Incentive Plan.
(10.26)* Form of Stock Option Agreement (phased vesting) is incorporated
by reference to Exhibit 10.17 of the Company's Form 10-K for the
year ended December 31, 1999.
(10.27)* Form of Special Stock Option Agreement (phased vesting) is
incorporated by reference to Exhibit 10.27 of the Company's Form
10-K for the year ended December 31, 1995 (File 1-1225).
(10.28)* Form of Special Stock Option Agreement (three-year vesting) is
incorporated by reference to Exhibit 10.28 of the Company's Form
10-K for the year ended December 31, 1995 (File 1-1225).
(10.29)* Amendment to Special Stock Option Agreement is incorporated
by reference to Exhibit 10.30 of the Company's Form 10-K for the
year ended December 31, 1996 (File 1-1225).
(10.30)* Form of Stock Option Agreement (transferable options) is
incorporated by reference to Exhibit 10.21 of the Company's Form
10-K for the year ended December 31, 1999.
(10.31)* Form of Restricted Stock Performance Award Agreement under the
1996 Stock Incentive Plan and 1999 Stock Incentive Plan
(Subsequent Award) is incorporated herein by reference to Exhibit
10.25 of the Company's 10-K for the year ended December 31, 2000.
(10.32)* Restricted Stock Trust Agreement under the 1993 Stock Incentive
Plan is incorporated by reference to Exhibit 10.23 of the
Company's Form 10-K for the year ended December 31, 1995 (File
1-1225).
(10.33)* Management Incentive Plan, as amended to date is incorporated
by reference to Exhibit 10.27 of the Company's Form 10-K for the
year ended December 31, 1999.
(10.34)* 1994 Restricted Stock Plan for Non-Employee Directors, as amended
to date, is incorporated by reference to Exhibit 10.3 of the
Company's Form 10-Q for the quarter ended June 30, 2001.
(10.35)* Stock Option Plan for Non-Employee Directors is incorporated by
reference to Exhibit 10.2 of the Company's Form 10-Q for the
quarter ended June 30, 2001.
(10.36)* Form of Stock Option Agreement under the Stock Option Plan for
Non-Employee Directors is incorporated by reference to Exhibit
10.30 of the Company's Form 10-K for the year ended December 31,
1999.
(10.37)*+ Savings Plan, as amended, to date.
*Denotes management contract or compensatory plan or arrangement required
to be filed as an exhibit hereto.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
21
(10.38)* Retirement Plan for Outside Directors, as amended on January 27,
1994, is incorporated by reference to Exhibit 10.12 of the
Company's Form 10-K for the year ended December 31, 1993 (File
1-1225).
(10.39)* Directors' Deferral Plan is incorporated by reference to Exhibit
10.4 of the Company's Form 10-Q for the quarter ended June 30,
2001.
(10.40)* Deferred Compensation Plan is incorporated by reference to
Exhibit 10.1 of the Company's Form 10-Q for the quarter ended
June 30, 2001.
(10.41)* Executive Retirement Plan is incorporated by reference to Exhibit
10.2 of the Company's Form 10-Q for the quarter ended September
30, 1997.
(10.42)* Executive Incentive Plan is incorporated by reference to Appendix
D of the Company's definitive Proxy Statement, filed March 20,
2002.
(10.43)*+ Supplemental Employee Savings Plan as amended to date.
(10.44)* Supplemental Executive Retirement Plan is incorporated by
reference to Exhibit 10.6 of the Company's Form 10-K for the year
ended December 31, 1990 (File 1-1225).
(10.45)* 2002 Stock Incentive Plan is incorporated by reference to
Appendix C of the Company's definitive Proxy Statement, filed
March 20, 2002.
(10.46)* American Cyanamid Company's Supplemental Executive Retirement
Plan is incorporated by reference to Exhibit 10K of American
Cyanamid Company's Form 10-K for the year ended December 31, 1988
(File 1-3426).
(10.47)* American Cyanamid Company's Supplemental Employees Retirement
Plan Trust Agreement, dated September 19, 1989, between American
Cyanamid Company and Morgan Guaranty Trust Company of New York is
incorporated by reference to Exhibit 10K of American Cyanamid
Company's Form 10-K for the year ended December 31, 1989 (File
1-3426).
(10.48)* American Cyanamid Company's ERISA Excess Retirement Plan is
incorporated by reference to Exhibit 10N of American Cyanamid
Company's Form 10-K for the year ended December 31, 1988 (File
1-3426).
(10.49)* American Cyanamid Company's Excess Retirement Plan Trust
Agreement, dated September 19, 1989, between American Cyanamid
Company and Morgan Guaranty Trust Company of New York is
incorporated by reference to Exhibit 10M of American Cyanamid
Company's Form 10-K for the year ended December 31, 1989 (File
1-3426).
*Denotes management contract or compensatory plan or arrangement required
to be filed as an exhibit hereto.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
22
(10.50)* Form of Severance Agreement entered into between the Company and
the executive officers specified therein and other executive
officers is incorporated by reference to Exhibit 10.43 of the
Company's Form 10-K for the year ended December 31, 1997.
(10.51)* Form of Severance Agreement entered into between the Company and
the executive officers specified therein is incorporated by
reference to Exhibit 10.1 of the Company's Form 10-Q for the
quarter ended June 30, 1998.
(10.52)* Agreement, dated as of March 6, 2001, by and between the
Corporation and John R. Stafford is incorporated by reference to
Exhibit 10.1 of the Company's Form 10-Q for the quarter ended
March 31, 2001.
(10.53)* Amendatory Agreement, dated as of March 6, 2001, by and between
the Corporation and John R. Stafford is incorporated by reference
to Exhibit 10.2 of the Company's Form 10-Q for the quarter ended
March 31, 2001.
(10.54)*+ Union Savings Plan.
(12)+ Computation of Ratio of Earnings to Fixed Charges.
(13)+ 2001 Annual Report to Stockholders. Such report, except for
those portions thereof which are expressly incorporated by
reference herein, is furnished solely for the information of the
Commission and is not to be deemed "filed" as part of this
filing.
(16) Letter from Arthur Andersen LLP to the Securities and Exchange
Commission, dated March 18, 2002, is incorporated herein by
reference to Exhibit 16 to the Current Form on Form 8-K, dated
March 18, 2002.
(21)+ Subsidiaries of the Company.
(23.1)+ Consent of Independent Accountants, Arthur Andersen LLP,
relating to their report dated January 24, 2002, consenting to
the incorporation thereof in Registration Statements on Form S-3
(File Nos. 33-45324 and 33-57339), Form S-4 (File No. 333-59642)
and on Form S-8 (File Nos. 2-96127, 33-24068, 33-41434, 33-53733,
33-55449, 33-45970, 33-14458, 33-50149, 33-55456, 333-15509,
333-76939, 333-67008, 333-64154 and 333-59668) by reference to
the Form 10-K of the Company filed for the year ended December
31, 2001.
*Denotes management contract or compensatory plan or arrangement required
to be filed as an exhibit hereto.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
23
(23.2) Consent of Independent Accountants, PricewaterhouseCoopers LLP,
relating to their report dated November 26, 2002, except for
paragraph 5 of Note 14 which is as of December 9, 2002,
consenting to the incorporation thereof in Registration
Statements on Form S-3 (File Nos. 33-45324 and 33-57339), Form
S-4 (File No. 333-59642) and on Form S-8 (File Nos. 2-96127,
33-24068, 33-41434, 33-53733, 33-55449, 33-45970, 33-14458,
33-50149, 33-55456, 333-15509, 333-76939, 333-67008, 333-64154
and 333-59668) by reference to the Form 10-K/A of the Company
filed for the year ended December 31, 2001.
(99)+ Cautionary Statements regarding "Safe Harbor" Provisions of the
Private Securities Litigation Reform Act of 1995.
(99.1)+ Letter to the Securities and Exchange Commission regarding
Arthur Andersen LLP (pursuant to Temporary Note 3T).
(99.2) Final Nationwide Class Action Settlement Agreement, dated
November 18, 1999, as amended to date is incorporated by
reference to Exhibit 99.1 of the Company's Form 10-Q for the
quarter ended September 30, 2000.
(99.3) Consent Decree, dated October 3, 2000, is incorporated by
reference to Exhibit 99.2 of the Company's Form 10-Q for the
quarter ended September 30, 2000.
(99.4) Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
(99.5) Certification pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Denotes exhibits filed with the Company's Annual Report on Form 10-K on
March 29, 2002.
(b) Reports on Form 8-K
The following Current Reports on Form 8-K were filed by the
Company:
o December 18, 2001 relating to the proposed merger between
Amgen, Inc. and Immunex.
24
Consolidated Balance Sheets
(In thousands except share and per share amounts)
December 31, 2001 2000
- ---------------------------------------------------------------------------------------------------------
Assets
Cash and cash equivalents $ 1,744,734 $ 2,644,306
Marketable securities 1,281,988 341,031
Accounts receivable less allowances (2001-- $130,734 and 2000-- $144,150) 2,743,040 2,740,272
Inventories 1,754,971 1,531,727
Other current assets including deferred taxes 2,242,020 2,923,475
---------------------------
Total Current Assets 9,766,753 10,180,811
Property, plant and equipment:
Land 138,837 149,810
Buildings 3,294,004 2,694,612
Machinery and equipment 3,796,117 3,510,529
Construction in progress 1,715,493 1,223,282
---------------------------
8,944,451 7,578,233
Less accumulated depreciation 2,662,291 2,543,409
---------------------------
6,282,160 5,034,824
Goodwill and other intangibles, net of accumulated amortization
(2001-- $1,895,670 and 2000-- $1,739,368) 3,851,934 4,052,410
Other assets including deferred taxes 3,067,075 1,824,421
---------------------------
Total Assets $22,967,922 $21,092,466
===========================
Liabilities
Loans payable $ 2,097,354 $ 58,717
Trade accounts payable 672,457 595,233
Accrued expenses 4,257,523 8,831,459
Accrued federal and foreign taxes 229,847 256,650
---------------------------
Total Current Liabilities 7,257,181 9,742,059
Long-term debt 7,357,277 2,394,790
Other noncurrent liabilities 3,355,793 5,226,495
Accrued postretirement benefits other than pensions 925,098 911,029
---------------------------
Stockholders' Equity
$2.00 convertible preferred stock, par value $2.50 per share; 5,000,000
shares authorized 51 55
Common stock, par value $0.33 1/3 per share; 2,400,000,000 shares authorized
(outstanding shares: 2001-- 1,320,570,000 and 2000-- 1,311,774,000) 440,190 437,258
Additional paid-in capital 4,295,051 3,952,457
Retained earnings (accumulated deficit) 170,309 (899,118)
Accumulated other comprehensive loss (833,028) (672,559)
---------------------------
Total Stockholders' Equity 4,072,573 2,818,093
---------------------------
Total Liabilities and Stockholders' Equity $22,967,922 $21,092,466
===========================
The accompanying notes are an integral part of these Consolidated Financial Statements.
25
Consolidated Statements of Operations
(In thousands except per share amounts)
Years Ended December 31, 2001 2000 1999
- --------------------------------------------------------------------------------------------------------------
Net Revenue $14,128,514 $13,213,671 $11,815,138
----------------------------------------------
Cost of goods sold 3,388,776 3,269,418 3,022,556
Selling, general and administrative expenses 5,179,285 4,983,465 4,322,207
Research and development expenses 1,869,679 1,687,889 1,587,505
Interest expense, net 146,358 57,562 213,866
Other income, net (274,331) (161,039) (255,697)
Gain on sale of Immunex common stock -- (2,061,204) --
Termination fee -- (1,709,380) --
Litigation charges 950,000 7,500,000 4,750,000
Goodwill impairment -- 401,000 --
Special charges -- 347,000 82,000
----------------------------------------------
Income (loss) from continuing operations before
federal and foreign taxes 2,868,747 (1,101,040) (1,907,299)
Provision (benefit) for federal and foreign taxes 583,453 (200,000) (700,056)
----------------------------------------------
Income (Loss) from Continuing Operations 2,285,294 (901,040) (1,207,243)
Discontinued operations:
Income (loss) from operations of discontinued
agricultural products business (including federal
and foreign taxes of $57,289 and $1,551 for 2000
and 1999, respectively) -- 103,346 (19,878)
Loss on disposal of agricultural products business
(including federal and foreign tax charges of $855,248) -- (1,572,993) --
----------------------------------------------
Loss from Discontinued Operations -- (1,469,647) (19,878)
----------------------------------------------
Net Income (Loss) $ 2,285,294 $(2,370,687) $(1,227,121)
==============================================
Basic Earnings (Loss) per Share from Continuing Operations $ 1.74 $ (0.69) $ (0.92)
Basic Loss per Share from Discontinued Operations -- (1.12) (0.02)
----------------------------------------------
Basic Earnings (Loss) per Share $ 1.74 $ (1.81) $ (0.94)
==============================================
Diluted Earnings (Loss) per Share from Continuing Operations $ 1.72 $ (0.69) $ (0.92)
Diluted Loss per Share from Discontinued Operations -- (1.12) (0.02)
----------------------------------------------
Diluted Earnings (Loss) per Share $ 1.72 $ (1.81) $ (0.94)
==============================================
The accompanying notes are an integral part of these Consolidated Financial Statements.
26
Consolidated Statements of Changes in Stockholders' Equity
(In thousands except per share amounts)
$2.00 Retained Accumulated
Convertible Additional Earnings Other Total
Preferred Common Paid-in (Accumulated Comprehensive Stockholders'
Stock Stock Capital Deficit) Loss Equity
- ----------------------------------------------------------------------------------------------------------------------------------
Balance at January 1, 1999 $ 64 $ 437,466 $ 3,072,874 $ 6,432,729 $ (328,337) $ 9,614,796
----------------------------------------------------------------------------------------
Net loss (1,227,121) (1,227,121)
Currency translation adjustments (285,963) (285,963)
Unrealized gains on marketable securities 815 815
-------------
Comprehensive loss (1,512,269)
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (50) (50)
Common stock (per share: $0.905) (1,183,571) (1,183,571)
Common stock acquired for treasury (6,409) (39,505) (1,012,385) (1,058,299)
Common stock issued for stock options 3,376 230,894 234,270
Conversion of preferred stock
and other exchanges (3) 206 128,442 (8,775) 119,870
----------------------------------------------------------------------------------------
Balance at December 31, 1999 61 434,639 3,392,705 3,000,827 (613,485) 6,214,747
========================================================================================
- ----------------------------------------------------------------------------------------------------------------------------------
Net loss (2,370,687) (2,370,687)
Currency translation adjustments (70,496) (70,496)
Unrealized gains on marketable securities 11,422 11,422
-------------
Comprehensive loss (2,429,761)
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (46) (46)
Common stock (per share: $0.92) (1,201,431) (1,201,431)
Common stock acquired for treasury (2,472) (16,316) (374,289) (393,077)
Common stock issued for stock options 4,949 405,933 410,882
Conversion of preferred stock
and other exchanges (6) 142 170,135 (6,663) 163,608
International operations year end change 53,171 53,171
----------------------------------------------------------------------------------------
Balance at December 31, 2000 55 437,258 3,952,457 (899,118) (672,559) 2,818,093
========================================================================================
- ----------------------------------------------------------------------------------------------------------------------------------
Net income 2,285,294 2,285,294
Currency translation adjustments (166,200) (166,200)
Unrealized gains on derivative contracts 7,865 7,865
Unrealized losses on marketable securities (2,134) (2,134)
-------------
Comprehensive income 2,124,825
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (42) (42)
Common stock (per share: $0.92) (1,211,012) (1,211,012)
Common stock issued for stock options 2,774 221,857 224,631
Conversion of preferred stock
and other exchanges (4) 158 120,737 (4,813) 116,078
----------------------------------------------------------------------------------------
Balance at December 31, 2001 $ 51 $ 440,190 $ 4,295,051 $ 170,309 $ (833,028) $ 4,072,573
========================================================================================
The accompanying notes are an integral part of these Consolidated Financial Statements.
27
Consolidated Statements of Cash Flows
(In thousands)
Years Ended December 31, 2001 2000 1999
- -------------------------------------------------------------------------------------------------------------------------------
Operating Activities
Income (loss) from continuing operations $ 2,285,294 $ (901,040) $ (1,207,243)
Adjustments to reconcile income (loss) from continuing operations to net
cash provided from/(used for) operating activities of continuing operations:
Litigation charges 950,000 7,500,000 4,750,000
Gain on sale of Immunex common stock -- (2,061,204) --
Goodwill impairment -- 401,000 --
Special charges -- 347,000 82,000
Gains on sales of assets (249,399) (159,430) (205,739)
Depreciation 426,590 336,239 341,871
Amortization 181,139 198,810 199,307
Deferred income taxes 267,820 (814,282) (1,410,068)
Diet drug litigation payments (7,257,882) (3,966,845) (117,581)
Contributions to defined benefit pension plans (429,710) (17,554) (14,259)
Deconsolidation of Immunex -- (236,768) --
Changes in working capital, net of
businesses acquired, sold or deconsolidated:
Accounts receivable (68,984) (433,182) 164,588
Inventories (273,063) 31,188 (115,699)
Other current assets (395,764) 179,817 (170,478)
Trade accounts payable and accrued expenses 277,009 270,518 (73,946)
Accrued federal and foreign taxes (14,654) (393,330) (121,227)
Other items, net (145,231) 196,405 391,851
---------------------------------------------
Net cash provided from/(used for) continuing operations (4,446,835) 477,342 2,493,377
Net cash provided from/(used for) discontinued operations -- 77,600 (327,771)
---------------------------------------------
Net Cash Provided from/(Used for) Operating Activities (4,446,835) 554,942 2,165,606
=============================================
- -------------------------------------------------------------------------------------------------------------------------------
Investing Activities
Purchases of property, plant and equipment (1,924,265) (1,681,906) (937,435)
Proceeds from sale of agricultural products business -- 3,800,000 --
Proceeds from sale of Immunex common stock -- 2,404,875 --
Proceeds from sales of assets 408,230 256,192 327,730
Purchases of marketable securities (2,703,252) (677,802) (789,846)
Proceeds from sales and maturities of marketable securities 1,762,295 384,292 383,941
---------------------------------------------
Net Cash Provided from/(Used for) Investing Activities (2,456,992) 4,485,651 (1,015,610)
=============================================
- -------------------------------------------------------------------------------------------------------------------------------
Financing Activities
Net proceeds from/(repayments of) debt 7,007,156 (3,080,381) 1,593,468
Dividends paid (1,211,054) (1,201,477) (1,183,621)
Purchases of common stock for treasury -- (393,077) (1,058,299)
Exercises of stock options 224,631 410,882 234,270
---------------------------------------------
Net Cash Provided from/(Used for) Financing Activities 6,020,733 (4,264,053) (414,182)
---------------------------------------------
Effect of exchange rate changes on cash balances (16,478) (24,949) (25,418)
---------------------------------------------
Increase (Decrease) in Cash and Cash Equivalents (899,572) 751,591 710,396
Cash and Cash Equivalents, Beginning of Year 2,644,306 1,892,715 1,182,319
---------------------------------------------
Cash and Cash Equivalents, End of Year $ 1,744,734 $ 2,644,306 $ 1,892,715
=============================================
The accompanying notes are an integral part of these Consolidated Financial Statements.
28
Notes to Consolidated Financial Statements
1. Summary of Significant Accounting Policies
Principles of Consolidation: The accompanying Consolidated Financial Statements
include the accounts of Wyeth (formerly American Home Products Corporation) and
its majority-owned subsidiaries (the Company). The financial statements have
been prepared in accordance with accounting principles generally accepted in the
United States and necessarily include amounts based on judgments and estimates
made by management.
Effective January 1, 2000, the financial results of certain pharmaceutical
subsidiaries in Japan and India, which previously were included on an equity
basis, were consolidated in the financial results of the Company due to changes
which gave the Company the ability to exercise control over the operations of
these affiliates. Also, effective January 1, 2000, the financial results of
Immunex Corporation (Immunex), which previously were consolidated, were
deconsolidated and included on an equity basis in the results of operations of
the Company (see Note 2).
Prior to 2000, certain of the Company's international affiliates reported
their results of operations on a one-month lag (year ended November 30), which
allowed more time to compile results. In December 2000, the one-month lag was
eliminated, primarily to reflect the results of these operations on a more
timely basis. As a result, December 2000 income from continuing operations for
these entities of $53.2 million was recorded directly to stockholders' equity.
Description of Business: The Company is a U.S.-based multi-national
corporation engaged in the discovery, development, manufacture, distribution and
sale of a diversified line of products in two primary businesses:
Pharmaceuticals and Consumer Health Care. Pharmaceuticals include branded and
generic human ethical pharmaceuticals, biologicals, nutritionals, and animal
biologicals and pharmaceuticals. Principal products include women's health care
products, neuroscience therapies, cardiovascular products, infant nutritionals,
gastroenterology drugs, anti-infectives, vaccines, biopharmaceuticals, oncology
therapies, musculoskeletal therapies, hemophilia treatments and immunological
products. Principal animal health products include vaccines, pharmaceuticals,
endectocides and growth implants. Consumer Health Care products include
analgesics, cough/cold/allergy remedies, nutritional supplements, herbal
products, and hemorrhoidal, antacid, asthma and other relief items sold
over-the-counter. The Company sells its diversified line of products to
wholesalers, pharmacies, hospitals, physicians, retailers and other health care
institutions located in various markets in more than 140 countries throughout
the world. The Company is not dependent on any single customer or major group of
customers for its net revenue.
The Company is not dependent on any one patent-protected product or line of
products for a substantial portion of its net revenue or results of operations.
However, Premarin, one of the Company's conjugated estrogens products, which has
not had patent protection for many years, contributes significantly to net
revenue and results of operations.
29
Equity Method of Accounting: The Company accounts for its investments in 20%-
to 50%-owned companies using the equity method. Accordingly, the Company's share
of the earnings of these companies is included in Other income, net. The related
equity investment is included in Other assets including deferred taxes. At
December 31, 2001, Immunex was the Company's only material equity investment.
Immunex is a biopharmaceutical company that discovers, manufactures and markets
therapeutic products for the treatment of cancer and musculoskeletal disorders
such as rheumatoid arthritis. See Note 2 for discussion of Immunex-related
transactions in 2001 and 2000.
Cash Equivalents consist primarily of certificates of deposit, time deposits
and other short-term, highly liquid securities with original maturities of three
months or less and are stated at cost. The carrying value of cash equivalents
approximates fair value due to the short-term, highly liquid nature of cash
equivalents.
Marketable Securities consist of U.S. government or agency issues, commercial
paper, time deposits and corporate bonds and are stated at fair value, which
approximates cost due to the short-term, highly liquid nature of these
securities (less than six months). All marketable securities are
available-for-sale investments. The fair values are estimated based on current
market prices.
Inventories are valued at the lower of cost or market. Inventories valued
under the last-in, first-out (LIFO) method amounted to $319.9 million and $325.1
million at December 31, 2001 and 2000, respectively. The current value exceeded
the LIFO value by $59.5 million and $59.7 million at December 31, 2001 and 2000,
respectively. The remaining inventories are valued primarily under the first-in,
first-out (FIFO) method.
Inventories at December 31 consisted of:
(In thousands) 2001 2000
- ---------------------------------------------------------------
Finished Goods $653,108 $585,123
Work in progress 674,636 586,656
Materials and supplies 427,227 359,948
------------------------------
$1,754,971 $1,531,727
==============================
Property, Plant and Equipment is carried at cost. Depreciation is provided
over the estimated useful lives of the related assets, principally on the
straight-line method, as follows:
Buildings 10 - 50 years
Machinery and Equipment 3 - 20 years
Goodwill and Other Intangibles: Goodwill is defined as the excess of cost
over the fair value of net assets acquired and is amortized using the
straight-line method over various periods ranging from 15 to 40 years. Other
intangibles are recorded at cost and amortized from three to 10 years. The
Company continually reviews goodwill and other intangibles to evaluate whether
changes have occurred that would suggest such assets may be impaired. If
circumstances suggest an impairment, undiscounted future cash flows of such
assets acquired or purchased are estimated. If this estimate indicates that
goodwill or other intangibles are not recoverable, the carrying value of the
goodwill or other
30
intangibles is reduced to fair value by the estimated shortfall of future cash
flows on a discounted basis.
As of January 1, 2002, the Company will implement new authoritative
accounting guidance relating to both the initial recording and subsequent
impairment testing of goodwill and other intangibles. Refer to "Recently Issued
Accounting Standards" herein for discussion of the Company's implementation of
this new guidance.
Derivative Financial Instruments: The Company currently manages its exposure
to certain market risks, including foreign exchange and interest rate risks,
through the use of derivative financial instruments, and accounts for them in
accordance with Statement of Financial Accounting Standards (SFAS) Nos. 133,
Accounting for Derivative Instruments and Hedging Activities, and 138,
Accounting for Certain Derivative Instruments and Certain Hedging Activities.
On the date that the Company enters into a derivative contract, it designates
the derivative as: (1) a hedge of the fair value of a recognized asset or
liability (fair value hedge), (2) a hedge of a forecasted transaction or the
variability of cash flows that are to be received or paid in connection with a
recognized asset or liability (cash flow hedge), (3) a foreign currency fair
value or cash flow hedge (foreign currency hedge) or (4) a derivative instrument
that is not designated for hedge accounting treatment. For derivative contracts
that are designated and qualify as fair value hedges (including foreign currency
fair value hedges), the derivative instrument is marked-to-market with gains and
losses recognized in current period earnings to offset the respective losses and
gains recognized on the underlying exposure. For derivative contracts that are
designated and qualify as cash flow hedges (including foreign currency cash flow
hedges), the effective portion of gains and losses on these contracts is
reported as a component of accumulated other comprehensive income (loss) and
reclassified into earnings in the same period the hedged transaction affects
earnings. Any hedge ineffectiveness on cash flow hedges is immediately
recognized in earnings. The Company also enters into derivative contracts that
are not designated as hedging instruments. These derivative contracts are
recorded at fair value with the gain or loss recognized in current period
earnings. The Company does not hold any derivative instruments for trading
purposes. See Note 7 for further description of the Company's specific programs
to manage risk using derivative financial instruments.
Currency Translation: The majority of the Company's international operations
are translated into U.S. dollars using current foreign currency exchange rates
with currency translation adjustments reflected in Accumulated other
comprehensive loss in stockholders' equity. Currency translation adjustments
comprise the majority of Accumulated other comprehensive loss on the
Consolidated Balance Sheets and the Consolidated Statements of Changes in
Stockholders' Equity. Currency translation adjustments related to international
operations in highly inflationary economies are included in the results of
operations.
Revenue Recognition: Revenue from the sale of Company products is recognized
in Net revenue upon shipment to customers. Provisions for certain rebates,
product returns and discounts to customers are provided for as reductions in
determining Net revenue in the same period the related sales are recorded.
31
Revenue under co-promotion agreements from the sale of products developed by
other companies, such as the Company's arrangement with Immunex to co-promote
Enbrel and with King Pharmaceuticals, Inc. to co-promote Altace, is recorded as
alliance revenue, which is included in Net revenue. Such alliance revenue is
earned when the co-promoting company ships the product to a third party. Selling
and marketing expenses related to alliance revenue are included in Selling,
general and administrative expenses.
Shipping and Handling Costs, which include transportation to customers,
transportation to distribution points, warehousing and handling costs, are
included in Selling, general and administrative expenses. The Company typically
does not charge customers for shipping and handling costs. Shipping and handling
costs were $228.9 million, $212.5 million and $204.5 million in 2001, 2000 and
1999, respectively.
Rebates and Sales Incentives, which are deducted to arrive at Net revenue,
are offered to customers based upon volume purchases, the attainment of market
share levels, government mandates, coupons and consumer discounts. These costs
are recognized at the later of a) the date at which the related revenue is
recorded or b) the date at which the incentives are offered. Rebates and sales
incentives accruals included in Accrued expenses at December 31, 2001 and 2000
were $615.0 million and $482.7 million, respectively.
Research and Development Expenses are expensed as incurred. Upfront and
milestone payments made to third parties in connection with research and
development collaborations are expensed as incurred up to the point of
regulatory approval. Payments made to third parties subsequent to regulatory
approval are capitalized and amortized over the remaining useful life. Amounts
capitalized for such payments are included in Goodwill and other intangibles,
net of accumulated amortization.
32
Earnings (Loss) per Share: The following table sets forth the computations of
basic earnings (loss) per share and diluted earnings (loss) per share:
(In thousands except per share amounts)
Years Ended December 31, 2001 2000 1999
- ---------------------------------------------------------------------------------------------------------------------
Income (loss) from continuing operations less preferred dividends $ 2,285,252 $ (901,086) $ (1,207,293)
Loss from discontinued operations -- (1,469,647) (19,878)
-----------------------------------------------
Net income (loss) less preferred dividends $ 2,285,252 $ (2,370,733) $ (1,227,171)
Denominator:
Weighted average common shares outstanding 1,317,102 1,306,474 1,308,876
-----------------------------------------------
Basic earnings (loss) per share from continuing operations $ 1.74 $ (0.69) $ (0.92)
Basic loss per share from discontinued operations -- (1.12) (0.02)
-----------------------------------------------
Basic earnings (loss) per share $ 1.74 $ (1.81) $ (0.94)
===============================================
Income (loss) from continuing operations $ 2,285,294 $ (901,040) $ (1,207,243)
Loss from discontinued operations -- (1,469,647) (19,878)
-----------------------------------------------
Net income (loss) $ 2,285,294 $ (2,370,687) $ (1,227,121)
Denominator:
Weighted average common shares outstanding 1,317,102 1,306,474 1,308,876
Common stock equivalents of outstanding stock
options and deferred contingent common stock awards* 13,707 -- --
-----------------------------------------------
Total shares* 1,330,809 1,306,474 1,308,876
-----------------------------------------------
Diluted earnings (loss) per share from continuing operations* $ 1.72 $ (0.69) $ (0.92)
Diluted loss per share from discontinued operations* -- (1.12) (0.02)
-----------------------------------------------
Diluted earnings (loss) per share* $ 1.72 $ (1.81) $ (0.94)
===============================================
* The total weighted average common shares outstanding for diluted loss per
share for 2000 and 1999 did not include common stock equivalents, as the
effect would have been antidilutive.
Recently Issued Accounting Standards: In June 2001, the Financial Accounting
Standards Board (FASB) issued SFAS No. 142, Goodwill and Other Intangible
Assets, which supersedes APB Opinion No. 17, Intangible Assets, and addresses
how intangible assets that are acquired individually or with a group of other
assets should be accounted for in financial statements upon their acquisition.
The statement also addresses how goodwill and other intangibles should be
accounted for after they have been initially recognized in the financial
statements. With the adoption of SFAS No. 142, goodwill no longer is amortized
over its estimated useful life but is subject to at least an annual assessment
for impairment by applying a fair-value-based test. The same applies to other
intangibles, which have been determined to have indefinite useful lives. Other
intangibles with finite lives will continue to be amortized. The Company will
adopt SFAS No. 142 as of January 1, 2002.
In accordance with the adoption of SFAS No. 142, as of January 1, 2002, the
Company will cease amortizing goodwill. Included in Selling, general and
administrative expenses for 2001, 2000 and 1999 was approximately $160.5 million
($153.9 million after-tax or $0.12 per share-diluted), $179.6 million ($172.2
million after-tax or $0.13 per share-diluted) and $187.0 million ($179.2 million
33
after-tax or $0.14 per share-diluted) of goodwill amortization, respectively.
The Company currently is assessing the impact the new impairment testing
requirements may have on its financial position, results of operations and cash
flows.
In October 2001, the FASB issued SFAS No. 144, Accounting for the Impairment
or Disposal of Long-Lived Assets, which superseded existing guidance. The
provisions of SFAS No. 144 are effective for fiscal years beginning after
December 15, 2001 and generally are to be applied prospectively. SFAS No. 144
augments the criteria that would have to be met to classify an asset as
held-for-sale and refines the guidance in determining fair value in measuring an
impairment. The statement also requires expected future operating losses from
discontinued operations to be recorded in the period in which the losses are
incurred (rather than as of the date management commits to a formal plan to
dispose of a segment, as was previously required). In addition, the
qualifications for dispositions to be considered discontinued operations have
been expanded. The Company adopted this statement on January 1, 2002 and will
prospectively comply with all criteria outlined in SFAS No. 144.
In April 2001, the Emerging Issues Task Force (EITF) reached a consensus on
Issue No. 00-25, Vendor Income Statement Characterization of Consideration Paid
to a Reseller of the Vendor's Products. EITF No. 00-25 requires the cost of
certain vendor considerations to be classified as a reduction of revenue rather
than a marketing expense. The Company will adopt the provisions of EITF No.
00-25 as of January 1, 2002. The adoption of EITF No. 00-25 will result in
reclassifications of certain marketing expenses to revenues and will have no
effect on income from continuing operations. The Company does not anticipate the
adoption of this consensus to significantly affect the growth rate of net
revenues.
Reclassifications: Certain reclassifications have been made to the December
31, 2000 and 1999 Consolidated Financial Statements to conform with the December
31, 2001 presentation.
2. Acquisitions, Divestitures and Discontinued Operations
Discontinued Operations -- Cyanamid Agricultural Products
- ---------------------------------------------------------
On March 20, 2000, the Company signed a definitive agreement with BASF
Aktiengesellschaft (BASF) to sell the Cyanamid Agricultural Products business
which manufactures, distributes and sells crop protection and pest control
products worldwide. On June 30, 2000, the sale was completed, and BASF paid the
Company $3,800.0 million in cash and assumed certain debt. The Company recorded
an after-tax loss on the sale of this business and reflected this business as a
discontinued operation in the 2000 first quarter. The loss on the sale included
closing costs from the transaction and reflected operating income of the
discontinued business from April 1, 2000 through June 30, 2000 (the disposal
date). The loss on the sale was determined based on the difference in the book
value of the net assets sold compared with the price received for these net
assets. The sale of the Cyanamid Agricultural Products business produced a gain
for tax purposes and a loss for book purposes, as the Company did not get a
step-up in cost basis for tax purposes. This divergence, primarily caused by
goodwill, was included in the basis for book purposes, but was not included in
the basis for tax purposes. The lower tax basis created a taxable gain that
required a tax provision of approximately $855.2 million. This
34
tax provision was combined with the pre-tax book loss of approximately $717.8
million for a total after-tax loss on the sale of the business of $1,573.0
million or $1.20 per share-diluted. The Consolidated Financial Statements and
related Notes for the period ended December 31, 1999 have been restated, where
applicable, to reflect the Cyanamid Agricultural Products business as a
discontinued operation.
Operating results of discontinued operations were as follows:
Statement of Operations
(In thousands except per share amounts) -----------------------
Years Ended December 31, 2000 1999
- --------------------------------------------------------------------------
Net revenue $546,790 $1,668,980
Income (loss) before federal and foreign taxes 160,635 (18,327)
Provision for federal and foreign taxes 57,289 1,551
-----------------------
Income (loss) from operations of discontinued
agricultural products business 103,346 (19,878)
Loss on disposal of agricultural
products business (including federal and
foreign tax charges of $855,248) (1,572,993) -
-----------------------
Loss from discontinued operations $(1,469,647) $(19,878)
=======================
Diluted loss per share from
discontinued operations $(1.12) $(0.02)
=======================
Immunex Transactions:
2001 Proposed Acquisition of Immunex by Amgen
- ---------------------------------------------
In December 2001, Amgen Inc. (Amgen) and Immunex signed a definitive agreement
providing for Amgen, the world's largest biotechnology company, to acquire
Immunex in a merger transaction. Under the terms of the agreement, each share of
Immunex common stock will be exchanged for 0.44 shares of Amgen common stock and
$4.50 in cash. The transaction has been structured as a tax-free reorganization,
and Immunex shareholders will not be taxed to the extent that they receive Amgen
stock.
As part of the agreement, Amgen will acquire the 41% ownership in Immunex
held by the Company at December 31, 2001 for the same consideration per share,
providing the Company with over $1,000.0 million in cash and approximately an 8%
ownership in Amgen. The Company has agreed to vote its shares in favor of the
transaction. The transaction is anticipated to close in the second half of 2002,
subject to approval by shareholders of both companies, as well as customary
regulatory approvals. The Company and Immunex co-promote Enbrel in the United
States and Canada with the Company having exclusive international rights to the
product. The financial aspects of the existing licensing and marketing rights to
Enbrel remain unchanged.
35
2000 Transactions in Immunex Common Stock
- -----------------------------------------
In October 2000, the Company increased its ownership in Immunex from
approximately 53% to approximately 55% by converting a $450.0 million
convertible subordinated note into 15,544,041 newly issued shares of common
stock of Immunex. In November 2000, through a public equity offering, the
Company sold 60.5 million shares of Immunex common stock, and Immunex sold 20
million shares of newly issued Immunex common stock. Proceeds to the Company
were approximately $2,404.9 million resulting in a gain on the sale of $2,061.2
million ($1,414.9 million after-tax or $1.08 per share-diluted). Included in the
gain on the sale was a noncash pre-tax gain of $303.2 million ($200.2 million
after-tax), representing the Company's increase in its proportionate share of
the net book value of Immunex from Immunex's issuance of 20 million shares of
its common stock at a price above the net book value per share owned by the
Company. The Company used the net proceeds from the sale of its Immunex common
stock to reduce outstanding commercial paper and for other general corporate
purposes.
The public equity offering reduced the Company's ownership in Immunex from
approximately 55% to approximately 41%, which represented the ownership at
December 31, 2001 and 2000. As a result of the reduction in ownership below 50%,
the Company included the financial results of Immunex on an equity basis
retroactive to January 1, 2000.
3. Termination Fee, Goodwill Impairment and Special Charges
Termination Fee
- ---------------
On November 3, 1999, the Company and Warner-Lambert Company entered into an
agreement to combine the two companies in a merger-of-equals transaction. On
February 6, 2000, the merger agreement was terminated. The Company recorded
income of $1,709.4 million ($1,111.1 million after-tax or $0.85 per
share-diluted) resulting from the receipt of a $1,800.0 million termination fee
provided for under the merger agreement offset, in part, by certain related
expenses.
Goodwill Impairment
- -------------------
Based on projected profitability and future cash flows associated with generic
pharmaceuticals and the Solgar consumer health care product line, it was
determined that goodwill related to these product lines, at December 31, 2000,
was impaired. As a result, the Company recorded a charge of $401.0 million
($341.0 million after-tax or $0.26 per share-diluted) in 2000 to write down the
carrying value of goodwill, to fair value, based upon discounted future cash
flows.
Special Charges
- ---------------
Voluntary Market Withdrawals
In November 2000, the U.S. Food and Drug Administration (FDA) requested that the
pharmaceutical industry voluntarily stop producing and distributing products
containing phenylpropanolamine (PPA). The Company immediately ceased global
production and shipments of any products containing PPA and voluntarily withdrew
any such products from customer warehouses and retail store shelves. As a
result, the Company recorded a
36
special charge of $80.0 million ($52.0 million after-tax or $0.04 per
share-diluted) to provide primarily for product returns and the write-off of
inventory. The Company already had reformulated a majority of the products
involved in the voluntary market withdrawal and began shipping these products in
the United States at the end of November 2000. At December 31, 2001, all amounts
provided for the PPA voluntary market withdrawal had been utilized.
During the 1999 second quarter, the Company recorded a special charge
aggregating $82.0 million ($53.0 million after-tax or $0.04 per share-diluted)
for estimated costs associated with the suspension of shipments and the
voluntary market withdrawal of RotaShield, the Company's rotavirus vaccine. At
December 31, 2001, all amounts provided for the RotaShield voluntary market
withdrawal had been utilized.
Product Discontinuations
During the 2000 fourth quarter, the Company recorded a special charge of $267.0
million ($173.0 million after-tax or $0.13 per share-diluted) related to the
discontinuation of certain products manufactured at the Company's Marietta,
Pennsylvania and Pearl River, New York facilities. Approximately $227.1 million
related to noncash costs for fixed asset impairments and inventory write-offs,
with the remainder of the charge covering severance obligations, idle plant
costs and contract termination costs. During 2001, approximately $7.8 million of
these costs were paid, leaving an accrual of $32.1 million at December 31, 2001.
The timing of the remaining costs to be incurred has been delayed as the Company
has continued to produce certain products in response to a potential market
shortage for these products and the related medical necessity. As a result, the
majority of the remaining costs will not be expended until 2003.
Restructuring Charge and Related Asset Impairments
In December 1998, the Company recorded a special charge for restructuring and
related asset impairments of $321.2 million ($224.8 million after-tax or $0.17
per share-diluted) to recognize the costs of the reorganization of the
pharmaceutical and nutritional supply chains (primarily in the Asian-Pacific and
Latin American regions), the reorganization of the U.S. pharmaceutical and
consumer health care distribution systems, and a reduction in personnel from the
globalization of certain business units. The reorganization of the
pharmaceutical and nutritional supply chains will result in the closure of 14
plants (nine pharmaceutical and five nutritional). The reorganization of the
U.S. pharmaceutical and consumer health care distribution systems resulted in
the closure of three distribution centers. The restructuring ultimately will
result in the elimination of 3,900 positions offset, in part, by 1,000 newly
created positions in the same functions at other locations. The components of
this charge were as follows: (i) personnel costs of $120.0 million, (ii) noncash
costs for fixed asset write-offs of $115.2 million and (iii) other closure/exit
costs of $86.0 million. The noncash costs of $115.2 million reduced the carrying
value of the fixed assets to their estimated fair value, taking into
consideration depreciation expected during the transition period, which was
determined by experience with similar properties and external appraisals. These
fixed assets, with a fair value of $11.6 million, have remained operational
during the transition period of obtaining the necessary regulatory approvals to
relocate these operations to new and existing facilities. Since these fixed
37
assets have remained in use, depreciation was not suspended and will be
recognized over the transition period. Other closure/exit costs are a direct
result of the restructuring plan. The majority of the other closure/exit costs
are anticipated to be paid after the facilities cease production and prior to
disposition. These costs include non-cancelable operating leases, security,
utilities, maintenance, property taxes and other related costs that will be paid
during the disposal period. Due to the specialized nature of these facilities,
the majority of the costs will be paid over a two- to three-year period as
product transfers are approved by regulatory authorities and manufacturing sites
are closed. However, delays in obtaining certain regulatory approvals and other
closure delays will cause certain costs to be paid after that period.
At December 31, 2001, approximately 3,700 positions had been eliminated, and
two distribution centers owned by the Company and a leased distribution center
had been closed. Of 14 manufacturing plants originally anticipated to be closed,
eight were closed in 2000 and two were closed during 2001. The Company currently
anticipates utilizing the remainder of the restructuring accruals in 2002,
assuming no further delays in regulatory approvals.
Activity in the restructuring accruals from continuing operations was as
follows:
Personnel Fixed Asset Other Closure/
(In thousands) Costs Write-offs Exit Costs Total
- ----------------------------------------------------------------------------------------------------------
Restructuring accruals at inception $119,975 $115,225 $86,000 $321,200
Cash expenditures (527) -- (922) (1,449)
Write-offs of fixed assets -- (115,225) -- (115,225)
---------------------------------------------------------
Restructuring accruals at December 31, 1998 119,448 -- 85,078 204,526
Cash expenditures (64,695) -- (5,817) (70,512)
---------------------------------------------------------
Restructuring accruals at December 31, 1999 54,753 -- 79,261 134,014
Cash expenditures (48,504) -- (19,626) (68,130)
---------------------------------------------------------
Restructuring accruals at December 31, 2000 6,249 -- 59,635 65,884
Redistributions 14,000 -- (14,000) --
Cash expenditures (11,212) -- (15,016) (26,228)
---------------------------------------------------------
Restructuring accruals at December 31, 2001 $9,037 $ -- $30,619 $39,656
=========================================================
During the 2001 second quarter, the Company made redistribution adjustments
between categories to increase accrual balances for personnel costs by $14.0
million and to decrease other closure/exit costs by $14.0 million. These
redistributions were necessary due to higher than expected enhanced pension
benefits and outplacement costs for non-U.S. employees, updated forecasts of
employees within the affected facilities, and lower than expected other
closure/exit costs. The original scope of the restructuring program remains
substantially unchanged.
38
4. Debt and Financing Arrangements
The Company's debt at December 31 consisted of:
(In thousands) 2001 2000
- ----------------------------------------------------------------------------
Commercial paper $4,817,205 $798,029
Notes payable:
6.50% notes due 2002 250,000 250,000
5.875% notes due 2004 500,000 --
7.90% notes due 2005 1,000,000 1,000,000
6.25% notes due 2006 1,000,000 --
6.70% notes due 2011 1,500,000 --
7.25% debentures due 2023 250,000 250,000
Pollution control and industrial revenue bonds:
1.8%-5.8% due 2006-2020 83,950 85,150
Other debt:
0.5%-17.0% due 2002-2009 40,674 70,328
Fair value of interest rate swaps 12,802 --
-------------------------
9,454,631 2,453,507
Less current portion 2,097,354 58,717
-------------------------
$7,357,277 $2,394,790
=========================
The fair value of the Company's outstanding debt was $9,607.7 million and
$2,506.6 million at December 31, 2001 and 2000, respectively. The fair value of
the Company's outstanding debt was estimated based on market prices.
The weighted average interest rate on the commercial paper outstanding at
December 31, 2001 and 2000 was 2.09% and 6.45%, respectively. The commercial
paper had original maturities that did not exceed 270 days and a weighted
average remaining maturity of 37 days and 35 days at December 31, 2001 and 2000,
respectively.
Revolving Credit Facilities
The Company maintains a $2,000.0 million credit facility, which supports
borrowings under the commercial paper program and terminates on July 31, 2002.
Since the $2,000.0 million credit facility terminates in less than one year,
commercial paper outstanding of $1,817.2 million, supported by this facility,
was classified as current debt in Loans payable as of December 31, 2001.
In addition, in March 2001, the Company obtained new credit facilities
totaling $6,000.0 million. The new credit facilities included a $3,000.0
million, 364-day credit facility (which also supports borrowings under the
commercial paper program) and a 364-day bridge facility to capital markets,
which was terminated on March 30, 2001 as discussed below. Any borrowings under
the new 364-day credit facility that are outstanding upon its termination in
March 2002 are extendible for an additional year. The portion of commercial
paper outstanding at December 31, 2001 supported by the $3,000.0 million,
364-day credit facility was classified as Long-term debt since the Company
intends, and has the ability, to refinance these obligations through the
issuance of additional commercial paper or through the use of its $3,000.0
million credit facility as described above.
39
The proceeds from the credit facilities may be used to support commercial
paper and the Company's general corporate and working capital requirements,
including payments related to the Redux and Pondimin diet drug litigation. The
credit facilities contain substantially identical financial and other covenants,
representations, warranties, conditions and default provisions. At December 31,
2001 and 2000, there were no borrowings outstanding under the facilities.
In March 2002, the Company renewed the $3,000.0 million credit facility for
an additional 364-day term and reduced the $2,000.0 million credit facility to
$1,000.0 million until it matures on July 31, 2002.
Bridge Facility and Notes
The new credit facilities also included a $3,000.0 million, 364-day bridge
facility, which was terminated when the Company issued $3,000.0 million of
Senior Notes (the Notes) on March 30, 2001. These Notes consisted of three
tranches, which pay interest semiannually on March 15 and September 15, in a
transaction exempt from registration under the Securities Act of 1933, as
amended (the Securities Act), pursuant to Rule 144A, as follows:
o $500.0 million 5.875% Notes due March 15, 2004
o $1,000.0 million 6.25% Notes due March 15, 2006
o $1,500.0 million 6.70% Notes due March 15, 2011
As of June 15, 2001, pursuant to an exchange offer made by the Company,
substantially all the Notes had been exchanged for new notes which have
substantially identical terms and which have been registered under the
Securities Act.
The interest rate payable on each series of Notes is subject to an increase
of 0.25 percentage points per level of downgrade in the Company's credit rating
by Moody's or S&P. However, the total adjustment to the interest rate for the
series of Notes cannot exceed two percentage points. There is no adjustment to
the interest rate payable on each series of Notes for the first single level
downgrade in the Company's credit rating by S&P. In the case of the $1,500.0
million 6.70% Notes, the interest rate in effect on March 15, 2006 for such
Notes will, thereafter, become the effective interest rate until maturity on
March 15, 2011. The Company would incur a total of approximately $7.5 million of
additional annual interest expense for every 0.25 percentage point increase in
the interest rate. If Moody's or S&P subsequently were to increase the Company's
credit rating, the interest rate payable on each series of Notes is subject to a
decrease of 0.25 percentage points for each level of credit rating increase. The
interest rate payable for the series of Notes cannot be reduced below the
original coupon rate of each series of Notes.
40
The Company entered into two $750.0 million notional amount interest rate
swaps relating to the $1,500.0 million 6.70% Notes under which the Company
effectively converted the fixed rate on these Notes to a floating rate of
interest which is based on LIBOR. See Note 7 for further discussion of the
interest rate swaps.
In addition to the $3,000.0 million of Notes described above, the Company has
outstanding the following non-callable, unsecured and unsubordinated debt
instruments:
o $250.0 million 6.50% Notes due October 2002, interest payments due on
April 15 and October 15
o $1,000.0 million 7.90% Notes due February 2005, interest payments due
on February 15 and August 15
o $250.0 million 7.25% debentures due March 2023, interest payments due
on March 1 and September 1
The aggregate maturities of debt during the next five years and thereafter at
December 31, 2001 are as follows:
(In thousands)
- -----------------------------------------------------------------
2002 $2,097,354
2003 7,929
2004 505,917
2005 1,001,380
2006 1,012,480
Thereafter 1,829,571
----------
6,454,631
Commercial paper classified as Long-term debt 3,000,000
----------
Total debt $9,454,631
==========
Interest payments in connection with the Company's debt obligations for the
years ended December 31, 2001, 2000 and 1999 amounted to $331.7 million, $343.0
million and $294.8 million, respectively.
Interest expense, net included interest income of $154.8 million, $181.3
million and $129.4 million in 2001, 2000 and 1999, respectively. Interest
capitalized in connection with capital projects was $94.3 million, $43.3 million
and $15.4 million in 2001, 2000 and 1999, respectively.
41
5. Other Noncurrent Liabilities
Other noncurrent liabilities include reserves for the Redux and Pondimin
litigation (see Note 12), reserves relating to income taxes, environmental
matters, product liability and other litigation, as well as restructuring,
pension and other employee benefit liabilities, and minority interests.
The Company has responsibility for environmental, safety and cleanup
obligations under various local, state and federal laws, including the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund. At December 31, 2001, the Company was a party to, or
otherwise involved in, legal proceedings directed at the cleanup of 53 Superfund
sites.
It is the Company's policy to accrue for environmental cleanup costs if it is
probable that a liability has been incurred and an amount is reasonably
estimable. In many cases, future environmental-related expenditures cannot be
quantified with a reasonable degree of accuracy. Environmental expenditures that
relate to an existing condition caused by past operations that do not contribute
to current or future results of operations are expensed. As investigations and
cleanups proceed, environmental-related liabilities are reviewed and adjusted as
additional information becomes available. The aggregate environmental-related
accruals were $364.2 million and $378.6 million at December 31, 2001 and 2000,
respectively. Environmental-related accruals have been recorded without giving
effect to any possible future insurance proceeds or the timing of payments. See
Note 12 for discussion of contingencies.
In 2000, the Company introduced a new incentive program to employees, the
Performance Incentive Award Program (PIA), which awards employees based on the
Company's operating results and the individual employee's performance.
Substantially all U.S. and Puerto Rico exempt employees, who are not subject to
other incentive programs, and key international employees are eligible to
receive cash awards under PIA. The value of PIA awards for 2001 and 2000 was
$117.3 million and $94.7 million, respectively. In 1999, cash bonuses totaling
$38.8 million were paid to key employees. Through 1998, the Company provided
incentive awards under the Management Incentive Plan (MIP), which provided for
cash and deferred contingent common stock awards to key employees. Deferred
contingent common stock awards plus accrued dividends, related to the MIP
program, totaling 875,206 shares were outstanding at December 31, 2001.
6. Pensions and Other Postretirement Benefits
Pensions: The Company sponsors various retirement plans for most full-time
employees. These defined benefit and defined contribution plans cover all U.S.
and certain international locations. Total pension expense from continuing
operations for both defined benefit and defined contribution plans for 2001,
2000 and 1999 was $141.9 million, $107.7 million and $95.5 million,
respectively. Pension expense from continuing operations for defined
contribution plans for 2001, 2000 and 1999 totaled $67.0 million, $62.9 million
and $61.6 million, respectively.
Pension plan benefits for defined benefit plans are based primarily on
participants' compensation and years of credited service. Investment
responsibility for the pension plan assets is assigned to outside investment
42
managers and is limited to certain asset allocation criteria and investment
guidelines established by the Company. Employees do not have any ability to
determine the investment allocation of the pension plan assets.
Generally, contributions to defined contribution plans are based on a
percentage of the employee's compensation. The Company's 401(k) savings plans
have been established for substantially all U.S. employees. Certain employees
are eligible to enroll in the plan on their hire date and can contribute between
1% and 16% of their annual pay. The Company provides a matching contribution to
eligible participants of 50% on the first 6% of annual pay contributed to the
plan, or a maximum of 3% of annual pay. Employees can direct their contributions
and the Company's matching contributions into any of the funds offered. These
funds provide participants with a cross section of investing options, including
the Company's common stock. All contributions to the Company's common stock,
whether by employee or employer, can be transferred to other fund choices daily.
Other Postretirement Benefits: The Company provides postretirement health
care and life insurance benefits for retired employees of most domestic
locations and Canada. Most full-time employees become eligible for these
benefits after attaining specified age and service requirements.
Although the Company sold the Cyanamid Agricultural Products business in 2000
(see Note 2), which was accounted for as a discontinued operation, the pensions
and other postretirement benefits were excluded from the sale for U.S. plans
since employees of the Cyanamid Agricultural Products business accrued benefits
in plans that encompassed other business segments. Except for one pension plan
in Germany, all international plans will continue to be maintained by the
Company to pay benefits that were accrued prior to the sale. Accordingly,
projected benefit obligations, fair value of plan assets and (prepaid)/accrued
benefit costs were not restated, except to reflect the sale of the pension plan
in Germany. However, components of net periodic benefit cost from continuing
operations were restated to reflect the Cyanamid Agricultural Products business
as a discontinued operation.
43
The change in projected benefit obligation, change in plan assets,
reconciliation of funded status and amounts recognized in the Consolidated
Balance Sheets for the Company's defined benefit plans (principally U.S. plans)
for 2001 and 2000 were as follows:
Pensions Other Postretirement Benefits
---------------------------- -----------------------------
Change in Projected Benefit Obligation (In thousands) 2001 2000 2001 2000
- ------------------------------------------------------------------------------------------------------------------------
Projected benefit obligation at January 1 $ 3,210,575 $ 3,005,665 $ 1,020,330 $ 1,076,298
Consolidation of Japan benefit plan -- 186,327 -- --
Service cost 78,634 74,656 24,179 20,460
Interest cost 226,786 225,248 76,966 77,666
Service and interest cost - discontinued operations -- 3,074 -- 2,189
Amendments 9,796 11,235 -- 16,952
Net actuarial loss/(gain) 104,938 71,158 227,758 (72,589)
Curtailments/settlements -- (39,826) -- (24,289)
Benefits paid (284,603) (296,613) (78,516) (75,900)
Currency translation adjustment (30,094) (30,349) (632) (457)
----------------------------------------------------------------
Projected benefit obligation at December 31 $ 3,316,032 $ 3,210,575 $ 1,270,085 $ 1,020,330
================================================================
Pensions Other Postretirement Benefits
---------------------------- -----------------------------
Change in Plan Assets (In thousands) 2001 2000 2001 2000
- -------------------------------------------------------------------------------------------------------------
Fair value of plan assets at January 1 $ 2,816,016 $ 3,001,154 $ -- $ --
Consolidation of Japan benefit plan -- 76,089 -- --
Actual return on plan assets (213,908) 34,607 -- --
Amendments 6,754 -- -- --
Company contributions 429,710 17,554 78,516 75,900
Benefits paid (284,603) (296,613) (78,516) (75,900)
Currency translation adjustment (15,347) (16,775) -- --
----------------------------------------------------------------
Fair value of plan assets at December 31 $ 2,738,622 $ 2,816,016 $ -- $ --
================================================================
Pensions Other Postretirement Benefits
--------------------------- -----------------------------
Reconciliation of Funded Status (In thousands) 2001 2000 2001 2000
- ----------------------------------------------------------------------------------------------------------------
Funded status $ 577,410 $ 394,559 $ 1,270,085 $ 1,020,330
Unrecognized net actuarial loss (603,051) (44,225) (243,292) (15,603)
Unrecognized prior service cost (57,193) (60,502) (16,695) (18,698)
Unrecognized net transition obligation (5,301) (8,266) -- --
---------------------------------------------------------------
(Prepaid)/accrued benefit costs $ (88,135) $ 281,566 $ 1,010,098 $ 986,029
===============================================================
Pensions
Amounts Recognized in the Consolidated ---------------------------
Balance Sheets (In thousands) 2001 2000
- ----------------------------------------------------------------------------
Prepaid benefit cost $ (212,967) (8,537)
Accrued benefit liability 124,832 290,103
In December 2001, the Company made a $400.0 million funding contribution to
the U.S. Non-bargaining defined benefit pension plan (largest U.S. plan) due
primarily to the decrease in the plan assets and, as a result, the anticipation
of future statutory funding requirements. The decline in the global equity
markets that occurred during 2001 contributed significantly to the decrease in
the plan assets. The impact of the negative market returns was attributable to
most of the increase in the unrecognized net actuarial loss since the difference
between the expected return and actual return on plan assets is deferred. The
net actuarial loss for other postretirement benefits of $227.8 million in 2001
44
resulted primarily from a change in the assumption for future increases in per
capita cost of health care benefits and other changes in actuarial assumptions.
There were no plan assets for the Company's other postretirement benefit
plans at December 31, 2001 and 2000 as postretirement benefits are funded by the
Company when claims are paid. The current portion of the accrued benefit
liability for other postretirement benefits was $85.0 million and $75.0 million
at December 31, 2001 and 2000, respectively.
At December 31, 2001 and 2000, the accumulated benefit obligations, which
represent the obligations of the defined benefit plans if the plans were
terminated and before considering plan assets, were $2,971.8 million and
$2,934.0 million, respectively.
Assumptions used in developing the projected benefit obligations at December
31 were as follows:
Pensions Other Postretirement Benefits
------------------------- -----------------------------------
Weighted Average Assumptions at December 31, 2001 2000 1999 2001 2000 1999
- -------------------------------------------------------------------------------------------------------------------
Discount rate 7.25% 7.5% 7.75% 7.25% 7.5% 7.75%
Rate of compensation increase 4.0% 4.0% 4.5% -- -- --
Expected return on plan assets 9.25% 9.5% 9.5% -- -- --
Increases in per capita cost of
health care benefits that gradually
decreases and is held constant thereafter
beginning in 2005 -- -- -- 9.5%-5.0% 7.0%-5.0% 7.5%-5.0%
The assumed health care cost trend rates have a significant effect on the
amounts reported. A one percentage point increase in the assumed health care
cost trend rates would increase the postretirement benefit obligation by $146.4
million and the total service and interest cost components from continuing
operations by $13.7 million. A one percentage point decrease in the assumed
health care cost trend rates would decrease the postretirement benefit
obligation by $122.3 million and the total service and interest cost components
from continuing operations by $11.3 million.
45
Net periodic benefit cost from continuing operations for 2001, 2000 and 1999
of the Company's defined benefit plans (principally U.S. plans) was as follows:
Components of Net Periodic Benefit Cost
from Continuing Operations (In thousands) Pensions Other Postretirement Benefits
- ----------------------------------------- -------------------------------- -------------------------------
2001 2000 1999 2001 2000 1999
---------------------------------------------------------------------
Service cost $78,634 $74,656 $69,056 $24,179 $20,460 $23,001
Interest cost 226,786 225,248 211,971 76,966 77,666 74,871
Expected return on plan assets (246,449) (270,131) (260,323) -- -- --
Amortization of prior service cost 11,720 10,704 10,734 2,003 330 339
Amortization of transition obligation 1,999 2,184 1,114 -- -- --
Recognized net actuarial loss 2,250 2,091 2,827 127 134 6,852
Curtailment gain -- -- (1,502) -- -- --
---------------------------------------------------------------------
Net periodic benefit cost
from continuing operations $74,940 $44,752 $33,877 $103,275 $98,590 $105,063
=====================================================================
Net periodic pension benefit cost from continuing operations was higher in
2001 compared with 2000 due primarily to the decrease in the expected return on
plan assets of the U.S. pension plans. The fair value of the U.S. pension plan
assets between 2000 and 1999 decreased by $270.2 million, which negatively
affected the amount of expected return on plan assets for 2001. Net periodic
pension benefit cost from continuing operations was higher in 2000 compared with
1999 due primarily to consolidating a subsidiary in Japan effective January 1,
2000 (see Note 1).
As a result of the sale of the Cyanamid Agricultural Products business, the
Company realized a curtailment gain related to the pension plans of $25.5
million. This curtailment gain was recorded in Loss on disposal of agricultural
products business.
7. Derivative Instruments and Foreign Currency Risk Management Programs
As of January 1, 2001, the Company adopted SFAS Nos. 133 and 138, which require
that all derivative financial instruments be measured at fair value and be
recognized as assets or liabilities on the balance sheet with changes in the
fair value of the derivatives recognized in either income (loss) from continuing
operations or accumulated other comprehensive income (loss), depending on the
timing and designated purpose of the derivative. The fair value of forward
contracts and interest rate swaps reflects the present value of the future
potential gain if settlement were to take place on December 31, 2001, with the
fair value of option contracts reflecting the present value of future cash flows
if the contract were settled on December 31, 2001. The impact on the Company's
financial position, results of operations and cash flows, upon adoption of these
pronouncements, was immaterial.
The Company currently engages in two primary programs to manage its exposure
to foreign currency risk. The two programs and the corresponding derivative
contracts outstanding as of December 31, 2001 were as follows:
1. Short-term foreign exchange forward contracts and swap contracts are
used to neutralize month-end balance sheet exposures. These contracts
essentially take the opposite currency position of that projected in
the month-end balance sheet to counterbalance the effect of any
currency movement. These derivative instruments
46
are not designated as hedges and are recorded at fair value with any
gains or losses recognized in current period earnings in accordance
with the requirements of SFAS Nos. 133 and 138. In 2001, the Company
recorded a gain of $28.7 million in Other income, net relating to
gains and losses on these foreign exchange forward contracts and swap
contracts. The $28.7 million consists of gains and losses from
contracts settled during 2001, as well as contracts outstanding at
December 31, 2001 that are recorded at fair value.
2. The Company uses foreign currency put options and foreign currency
forward contracts in its cash flow hedging program to cover foreign
currency risk related to international intercompany inventory sales.
These instruments are designated as cash flow hedges, and, in
accordance with SFAS Nos. 133 and 138, any unrealized gains or losses
are included in accumulated other comprehensive income (loss) with the
corresponding asset or liability recorded in the balance sheet. As of
December 31, 2001, $4.4 million after-tax of net gains relating to
these cash flow hedges was included in Accumulated other comprehensive
loss with the corresponding assets/liabilities recorded in Other
current assets including deferred taxes/Accrued expenses. The
unrealized net gains in Accumulated other comprehensive loss will be
reclassified into the Consolidated Statement of Operations when the
intercompany inventory is sold to a third party. As such, the Company
anticipates recognizing these net gains during the next six months.
Put option contracts outstanding as of December 31, 2001 expire no
later than June 2002. Occasionally the Company purchases foreign
currency put options outside of the cash flow hedging program to
protect additional intercompany inventory sales. These put options do
not qualify as cash flow hedges under SFAS Nos. 133 and 138 and were
recorded at fair value with all gains or losses, which were not
significant, recognized in current period earnings immediately.
In addition to the programs identified above, the Company has entered into a
foreign exchange forward contract to hedge against foreign exchange fluctuations
on a yen denominated long-term intercompany loan to the Company's Japanese
subsidiary. The forward contract has been designated as and qualifies for
foreign currency cash flow hedge accounting treatment. As of December 31, 2001,
the Company had recorded gains of $3.5 million after-tax in Accumulated other
comprehensive loss relating to this foreign exchange forward contract.
The Company also has entered into interest rate swaps to manage interest rate
exposures. The Company strives to achieve a desired balance between fixed-rate
and floating-rate debt and has entered into two effective fair value interest
rate swaps on its $1,500.0 million 6.70% Notes to ensure this desired balance
between fixed-rate and floating-rate debt. The interest rate swaps effectively
converted a portion of the Company's fixed-rate debt into floating-rate debt.
Interest expense on the $1,500.0 million 6.70% Notes is adjusted to include the
payments made or received under the interest rate swap agreements. The fair
value of the swaps relating to the $1,500.0 million 6.70% Notes, as of December
31, 2001, excluding accrued interest, was an asset of $12.8
47
million and has been recorded in Other assets including deferred taxes with the
corresponding adjustment recorded to the underlying 6.70% Notes in Long-term
debt.
8. Capital Stock
There were 2,400,000,000 shares of common stock and 5,000,000 shares of
preferred stock authorized at December 31, 2001 and 2000. Of the authorized
preferred shares, there is a series of shares (20,486 and 21,948 outstanding at
December 31, 2001 and 2000, respectively) which is designated as $2.00
convertible preferred stock. Each share of the $2.00 series is convertible at
the option of the holder into 36 shares of common stock. This series may be
called for redemption at $60.00 per share plus accrued dividends.
On October 7, 1999, the Company's Board of Directors declared a dividend of
one preferred share purchase right for each share of common stock outstanding on
October 18, 1999. The rights also apply to all future stock issuances. Each
right permits the holder, under certain circumstances and upon the occurrence of
certain events, to purchase from the Company one one-thousandth of a share of
Series A Junior Participating Preferred Stock of the Company (the Series A
Preferred Stock) at an exercise price of $225 per one one-thousandth of a share
of Series A Preferred Stock under a Rights Plan relating to such Series A
Preferred Stock. The 5,000,000 shares of preferred stock authorized will be used
for the exercise of any preferred share purchase rights. The Rights Plan has
provisions that are triggered if any person or group acquires beneficial
ownership of 15% or more of the outstanding common stock or acquires the Company
in a merger or other business combination (an Acquiring Person). In such event,
stockholders (other than the Acquiring Person) would receive stock of the
Company or the Acquiring Person, as the case may be, having a market value of
twice the exercise price along with substantially increased voting and dividend
rights, among other things. The rights expire on October 7, 2009, and prior to
there being an Acquiring Person, the Company may redeem the rights issued under
the Rights Plan for $0.01 per right. The Company can, for so long as the rights
are then redeemable, supplement or amend the Rights Plan in any respect without
the approval of any holders of the rights. At any time after the rights are no
longer redeemable, the Company may supplement or amend the Rights Plan in
certain respects provided that no such supplement or amendment shall adversely
affect the interests of the holders of Rights Certificates as such (other than
an Acquiring Person or an Affiliate or Associate of an Acquiring Person).
48
Changes in outstanding common shares during 2001, 2000 and 1999 were as
follows:
(In thousands except shares of preferred stock) 2001 2000 1999
- -----------------------------------------------------------------------------------------
Balance at January 1 1,311,774 1,303,916 1,312,399
Issued for stock options 8,550 15,123 10,589
Purchases of common stock
for treasury -- (7,414) (19,226)
Conversions of preferred stock
(1,462, 2,293, and 1,239 shares in 2001, 2000
and 1999, respectively) and other exchanges 246 149 154
--------------------------------------
Balance at December 31 1,320,570 1,311,774 1,303,916
======================================
The Company has a common stock repurchase program under which the Company is
authorized to repurchase common shares. At December 31, 2001, the Company was
authorized to repurchase 6,492,460 common shares in the future.
9. Stock Options
The Company has one Stock Option Plan and four Stock Incentive Plans. No further
grants may be made under the Stock Option Plan or the Stock Incentive Plan
approved in 1990. Under the Stock Incentive Plans, options to purchase a maximum
of 181,000,000 shares may be granted at prices not less than 100% of the fair
market value of the Company's common stock on the date the option is granted. At
December 31, 2001, there were 19,974,293 shares available for future grants
under the Stock Incentive Plans. In January 2002, the Board of Directors
adopted, subject to stockholder approval at the Company's annual meeting on
April 25, 2002, the 2002 Stock Incentive Plan under which 65,000,000 shares are
available for future grants.
The plans provide for the granting of incentive stock options as defined
under the Internal Revenue Code. Under the plans, grants may be made to selected
officers and employees of non-qualified stock options with a 10-year term or
incentive stock options with a term not exceeding 10 years. The plans also
provide for the granting of stock appreciation rights (SAR), which entitle the
holder to receive shares of the Company's common stock or cash equal to the
excess of the market price of the common stock over the exercise price when
exercised. At December 31, 2001, there were no outstanding SARs.
Each Stock Incentive Plan allows for, among other things, the issuance of up
to 8,000,000 shares (24,000,000 shares in the aggregate for all Stock Incentive
Plans) as restricted stock awards. Restricted stock awards representing 290,995,
148,900 and 148,850 units were granted in 2001, 2000 and 1999, respectively,
under the plans to certain employees, including key executives. Most of these
units are converted to shares of restricted stock based on the achievement of
certain performance criteria related to performance years 1999 through 2005. The
remaining units are converted generally at the end of four years.
Under the Stock Option Plan for Non-Employee Directors, a maximum of 250,000
shares may be granted to non-employee directors at 100% of the fair market value
of the Company's common stock on the date of the grant. Stock options granted to
49
non-employee directors were 36,000, 21,000 and 21,000 in 2001, 2000 and 1999,
respectively. Shares available for future grants at December 31, 2001 were
172,000.
Under the 1994 Restricted Stock Plan for Non-Employee Directors, a maximum of
100,000 restricted shares may be granted to non-employee directors. The
restricted shares granted to each non-employee director are not delivered prior
to the end of a five-year restricted period. At December 31, 2001, 64,800 shares
were available for future grants.
Stock option information related to the plans was as follows:
Weighted Weighted Weighted
Average Average Average
Exercise Exercise Exercise
Stock Options 2001 Price 2000 Price 1999 Price
- ----------------------------------------------------------------------------------------------------------------------
Outstanding at January 1 82,751,313 $ 43.74 85,244,130 $ 39.13 75,790,629 $ 30.53
Granted 28,360,196 56.89 16,496,678 56.51 21,945,755 62.00
Canceled (2,558,655) 57.36 (3,866,134) 58.32 (1,903,601) 51.83
Exercised (2001--$14.52 to
$62.31 per share) (8,549,782) 26.74 (15,123,361) 27.90 (10,588,653) 22.76
----------- ---------- ----------
Outstanding at December 31
(2001-- $14.52 to $65.19 per share) 100,003,072 48.57 82,751,313 43.74 85,244,130 39.13
=========== ========== ==========
Exercisable at December 31 57,205,798 41.93 51,830,094 35.31 52,789,450 28.27
=========== ========== ==========
The following table summarizes information regarding stock options
outstanding at December 31, 2001:
Options Outstanding Options Exercisable
- ----------------------------------------------------------------- -------------------------
Weighted Weighted Weighted
Average Average Average
Range of Number Remaining Exercise Number Exercise
Exercise Prices Outstanding Contractual Life Price Exercisable Price
- --------------------------------------------------------------------------------------------------
14.52 to 19.99 11,672,218 2.4 years $17.90 11,672,218 $17.90
20.00 to 29.99 4,253,391 3.9 years 26.34 4,253,391 26.34
30.00 to 39.99 12,442,005 4.8 years 36.18 12,442,005 36.18
40.00 to 49.99 624,588 7.1 years 45.93 446,583 46.22
50.00 to 59.99 52,067,568 8.4 years 55.25 16,380,958 52.38
60.00 to 65.19 18,943,302 7.6 years 62.30 12,010,643 62.33
----------- ----------
100,003,072 6.9 years 48.57 57,205,798 41.93
=========== ==========
The Company accounts for stock-based compensation using the intrinsic value
method. Accordingly, no compensation expense has been recognized for stock
options. If compensation expense for the Company's stock options issued in 2001,
2000 and 1999 had been determined based on the fair value method of accounting,
50
the Company's net income (loss) and earnings (loss) per share would have been
adjusted to the pro forma amounts indicated below:
(In thousands except per share amounts) 2001 2000 1999
- ---------------------------------------------------------------------------------------
Net income (loss) less preferred dividends:
As-reported $ 2,285,252 $ (2,370,733) $ (1,227,171)
Pro forma 2,084,564 (2,520,657) (1,312,238)
Basic earnings (loss) per share:
As-reported $ 1.74 $ (1.81) $ (0.94)
Pro forma 1.58 (1.93) (1.00)
Net income (loss):
As-reported $ 2,285,294 $ (2,370,687) $ (1,227,121)
Pro forma 2,084,606 (2,520,611) (1,312,188)
Diluted earnings (loss) per share*:
As-reported $ 1.72 $ (1.81) $ (0.94)
Pro forma 1.57 (1.93) (1.00)
* The total weighted average common shares outstanding for diluted loss per
share for 2000 and 1999 did not include common stock equivalents, as the
effect would have been antidilutive.
The fair value of issued stock options is estimated on the date of grant
using a variant of the Black-Scholes option pricing model incorporating the
following assumptions for stock options granted in 2001, 2000 and 1999,
respectively: expected volatility (the amount by which the stock price is
expected to fluctuate) of 32.1%, 31.2% and 25.0%; expected dividend yield of
1.6%, 1.6% and 2.2%; risk-free interest rate of 4.8%, 6.3% and 5.6%; and
expected life of five, five and four years. The weighted average fair value of
stock options granted during 2001, 2000 and 1999 was $17.76, $18.76 and $14.36
per option share, respectively.
10. Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss consists of changes in foreign currency
translation adjustments, net unrealized gains on derivative contracts and net
unrealized gains (losses) on marketable securities. The following table sets
forth the changes in each component of Accumulated other comprehensive loss:
Foreign Net Unrealized Net Unrealized Accumulated
Currency Gains on Gains (Losses) on Other
Translation Derivative Marketable Comprehensive
(In thousands) Adjustments(1) Contracts(2) Securities Loss
- ------------------------- -------------- --------------- ----------------- -------------
Balance January 1, 1999 $ (329,004) - $ 667 $ (328,337)
Period change (285,963) - 815 (285,148)
-------------- --------------- ----------------- -------------
Balance December 31, 1999 (614,967) - 1,482 (613,485)
Period change (70,496) - 11,422 (59,074)
-------------- --------------- ----------------- -------------
Balance December 31, 2000 (685,463) - 12,904 (672,559)
Period change (166,200) $ 7,865 (2,134) (160,469)
-------------- --------------- ----------------- -------------
Balance December 31, 2001 $ (851,663) $ 7,865 $ 10,770 $ (833,028)
============== =============== ================= =============
(1) Income taxes are generally not provided for foreign currency
translation adjustments, as such adjustments relate to permanent investments in
international subsidiaries.
(2) Deferred income tax provided for net unrealized gains on derivative
contracts in 2001 was $1,000.
51
11. Income Taxes
The provision (benefit) for federal and foreign income taxes from continuing
operations consisted of:
(In thousands)
Years Ended December 31, 2001 2000 1999
- -------------------------------------------------------------------
Current:
Federal ($96,805) $321,484 $290,020
Foreign 412,438 292,798 419,992
---------------------------------------
315,633 614,282 710,012
Deferred:
Federal 270,144 (836,883) (1,399,709)
Foreign (2,324) 22,601 (10,359)
---------------------------------------
267,820 (814,282) (1,410,068)
---------------------------------------
$583,453 ($200,000) ($700,056)
=======================================
Net deferred tax assets from inclusive of valuation allowances for certain
deferred tax assets were reflected on the Consolidated Balance Sheets at
December 31 as follows:
(In thousands) 2001 2000
- --------------------------------------------------------------------
Net current deferred tax assets $1,526,690 $2,595,662
Net noncurrent deferred tax assets 1,583,599 795,441
----------------------------
Net deferred tax assets $3,110,289 $3,391,103
============================
Deferred income taxes are provided for temporary differences between the
financial reporting basis and the tax basis of the Company's assets and
liabilities. Deferred tax assets result principally from the recording of
certain accruals and reserves, which currently are not deductible for tax
purposes, as well as net operating loss carryforwards generated primarily from
deductible payments associated with the Redux and Pondimin diet drug litigation.
Deferred tax liabilities result principally from tax on earnings expected to be
remitted to the United States and the use of accelerated depreciation for tax
purposes.
52
The components of the Company's deferred tax assets and liabilities at
December 31 were as follows:
(In thousands) 2001 2000
- ----------------------------------------------------------------------------------------
Deferred tax assets:
Diet drug product litigation accruals $650,192 $2,857,951
Product litigation and environmental
liabilities and other accruals 660,282 760,827
Postretirement, pension and other employee benefits 536,676 592,709
Net operating loss and other tax credit carryforwards 1,756,522 4,134
Goodwill impairment 52,837 60,000
Restructuring and product discontinuations 113,638 129,143
Inventory reserves 127,175 94,393
Investments and advances 31,869 38,894
Research and development costs 554,521 -
Intangibles 58,538 51,568
Other 40,375 63,437
----------------------------
Total deferred tax assets 4,582,625 4,653,056
----------------------------
Deferred tax liabilities:
Tax on earnings expected to be remitted to the U.S. (700,000) (700,000)
Depreciation (370,916) (277,512)
Pension benefits and other employee benefits (140,004) (54,751)
Equity investments (110,204) (102,945)
Other (101,630) (75,592)
----------------------------
Total deferred tax liabilities (1,422,754) (1,210,800)
----------------------------
Deferred tax asset valuation allowances (49,582) (51,153)
----------------------------
Net deferred tax assets $3,110,289 $3,391,103
============================
Valuation allowances have been established for certain deferred
tax assets related to environmental liabilities and other operating accruals as
the Company determined that it was more likely than not that these benefits will
not be realized. During 2001 and 2000, the valuation allowance decreased by $1.6
million and $100.3 million, respectively. The decrease of the valuation
allowance in 2000 related to a reduction in net operating loss carryforwards as
a result of the deconsolidation of Immunex (see Note 2).
The Company has provided $700.0 million of federal income taxes on unremitted
earnings from its international subsidiaries that may be remitted back to the
United States. Federal income taxes were not provided on unremitted earnings
expected to be permanently reinvested internationally. If federal income taxes
were provided, they would approximate $380.0 million.
Reconciliations between the Company's effective tax rate and the U.S.
statutory rate from continuing operations, excluding the diet drug litigation
charges in 2001, 2000 and 1999 (see Note 12), the effect of the termination fee
in 2000 (see Note 3), gain on the sale of Immunex common stock in 2000
53
(see Note 2), goodwill impairment in 2000 (see Note 3) and special charges in
2000 and 1999 (see Note 3), were as follows:
Tax Rate
Years Ended December 31, 2001 2000 1999
- ----------------------------------------------------------------------------------------
U.S. statutory rate 35.0% 35.0% 35.0%
Effect of Puerto Rico and Ireland manufacturing operations (9.1) (8.6) (9.0)
Research credits (2.1) (1.7) (1.4)
Goodwill amortization 1.2 1.5 1.8
Other, net (0.9) (0.7) 0.7
-------------------------
Effective tax rate from continuing operations 24.1% 25.5% 27.1%
=========================
Including the effect of the 2001 litigation charge (which had a 35.3% tax
benefit), the overall effective tax rate from continuing operations in 2001 was
20.3%. Including the effect of the termination fee and the gain on the sale of
Immunex common stock in 2000 (which had tax provisions of 35.0% and 31.4%,
respectively), and the tax benefits associated with the 2000 litigation charge,
goodwill impairment and special charges (with effective rates of 28.3%, 15.0%
and 35.2%, respectively), the overall effective tax rate from continuing
operations in 2000 was an 18.2% tax benefit. Including the effect of the 1999
litigation charge and special charge (which had 30.8% and 35.4% of tax benefits,
respectively), the overall effective tax rate from continuing operations in 1999
was a 36.7% tax benefit. The difference in the tax benefits related to the 2000
and 1999 litigation charges versus the statutory rate of 35.0% was caused by
provisions of $500.0 million and $200.0 million in 2000 and 1999, respectively,
for additional federal income taxes, net of tax credits, that may be paid if the
Company remits certain international earnings, taxed at a lower rate than in the
United States, to the United States for diet drug litigation settlement
payments.
Total income tax payments, net of tax refunds, for continuing and
discontinued operations in 2001, 2000 and 1999 amounted to $493.6 million,
$1,038.3 million and $717.2 million, respectively.
12. Contingencies and Litigation Charges
The Company is involved in various legal proceedings, including product
liability and environmental matters of a nature considered normal to its
business (see Note 5 for discussion of environmental matters). It is the
Company's policy to accrue for amounts related to these legal matters if it is
probable that a liability has been incurred and an amount is reasonably
estimable.
The Company has been named as a defendant in numerous legal actions relating
to the diet drugs Pondimin (which in combination with phentermine, a product
that was not manufactured, distributed or sold by the Company, was commonly
referred to as "fen-phen") or Redux, which the Company estimated were used in
the United States, prior to their 1997 voluntary market withdrawal, by
approximately 5.8 million people. These actions allege, among other things, that
the use of Redux and/or Pondimin, independently or in combination with the
prescription drug phentermine, caused certain serious conditions, including
valvular heart disease.
54
On October 7, 1999, the Company announced a nationwide, class action
settlement (the settlement) to resolve litigation brought against the Company
regarding the use of the diet drugs Redux or Pondimin. The settlement covers all
claims arising out of the use of Redux or Pondimin, except for claims of primary
pulmonary hypertension (PPH), and is open to all Redux or Pondimin users in the
United States, regardless of whether they have lawsuits pending.
On November 23, 1999, U.S. District Judge Louis C. Bechtle granted
preliminary approval of the settlement and directed that notice of the
settlement terms be provided to class members. The notice program began in
December 1999. In early May 2000, the district court held a hearing on the
fairness of the terms of the settlement, with an additional one-day hearing on
August 10, 2000. On August 28, 2000, Judge Bechtle issued an order approving the
settlement. Several appeals were taken from that order to the U.S. Court of
Appeals for the Third Circuit. All but one of those appeals was withdrawn during
2001, and, on August 15, 2001, the Third Circuit affirmed the approval of the
settlement. When no petitions to the U.S. Supreme Court for certiorari were
filed by January 2, 2002, the settlement was deemed to have received final
judicial approval on January 3, 2002.
Payments by the Company related to the settlement are made into settlement
Funds A and B (the settlement funds). Fund A is intended to cover refunds,
medical screening costs, additional medical services and cash payments,
education and research costs, and administration costs. Fund B will compensate
claimants with significant heart valve disease. Payments to provide settlement
benefits, if needed, may continue for approximately 16 years after final
judicial approval. Payments to the settlement funds in 2001, 2000 and 1999 were
$936.7 million, $383.0 million and $75.0 million, respectively.
Diet drug users choosing to opt out of the settlement class were required to
do so by March 30, 2000. The Company has resolved the claims of the majority of
these initial opt outs and continues to resolve the claims of the remaining
individuals.
The settlement agreement also gives class members who participate in the
settlement the opportunity to opt out of the settlement at two later stages,
although there are restrictions on the nature of claims they can pursue outside
of the settlement. Class members who are diagnosed with certain levels of
valvular regurgitation within a specified time frame can opt out following their
diagnosis and prior to receiving any further benefits under the settlement
(intermediate opt outs). Class members who are diagnosed with certain levels of
regurgitation and who elect to remain in the settlement, but who later develop a
more severe valvular condition, may opt out at the time the more serious
condition develops (back-end opt outs). Under either of these latter two opt out
alternatives, class members may not seek or recover punitive damages, may sue
only for the condition giving rise to the opt out right, and may not rely on
verdicts, judgments or factual findings made in other lawsuits.
On January 18, 2002, as collateral for the Company's financial obligations
under the settlement, the Company established a security fund in the amount of
$370.0 million and recorded such amount in Other assets including deferred
taxes. The funds are owned by the Company and will earn interest income for the
Company while residing in the security fund. The Company will be required to
deposit an additional $180.0 million in the
55
security fund if the Company's credit rating, as reported by both Moody's and
S&P, falls below investment grade.
The Company recorded an initial litigation charge of $4,750.0 million
($3,287.5 million after-tax or $2.51 per share-diluted), net of insurance, in
connection with the Redux and Pondimin litigation in 1999, an additional charge
of $7,500.0 million in 2000 ($5,375.0 million after-tax or $4.11 per
share-diluted), and a third litigation charge of $950.0 million ($615.0 million
after-tax or $0.46 per share-diluted) in the 2001 third quarter. The combination
of these three charges represents the estimated total amount required to resolve
all diet drug litigation, including anticipated funding requirements for the
nationwide, class action settlement, anticipated costs to resolve the claims of
any members of the settlement class who in the future may exercise an
intermediate or back-end opt out right, costs to resolve the claims of PPH
claimants and initial opt out claimants, and administrative and litigation
expenses.
At December 31, 2001, $1,857.7 million of the litigation accrual remained;
$1,150.0 million and $707.7 million were included in Accrued expenses and Other
noncurrent liabilities, respectively. At December 31, 2000, $8,165.6 million of
the litigation accrual remained; $5,900.0 million and $2,265.6 million were
included in Accrued expenses and Other noncurrent liabilities, respectively.
Payments to the nationwide, class action settlement funds, individual settlement
payments, legal fees and other items were $7,257.9 million, $3,966.8 million and
$117.6 million for 2001, 2000 and 1999, respectively.
The Company is self-insured against ordinary product liability risks and has
liability coverage, in excess of certain limits and subject to certain policy
ceilings, from various insurance carriers.
In the opinion of the Company, although the outcome of any legal proceedings
cannot be predicted with certainty, the ultimate liability of the Company in
connection with its legal proceedings will not have a material adverse effect on
the Company's financial position but could be material to the results of
operations and cash flows in any one accounting period.
The Company leases certain property and equipment for varying periods under
operating leases. Future minimum rental payments under non-cancelable operating
leases from continuing operations with terms in excess of one year in effect at
December 31, 2001 are as follows:
(In thousands)
--------------------------------------------------------------
2002 $80,845
2003 74,312
2004 55,546
2005 50,214
2006 46,687
Thereafter 35,289
--------
Total rental commitments $342,893
========
56
Rental expense from continuing operations for all operating leases was $133.7
million, $128.2 million and $135.1 million in 2001, 2000 and 1999, respectively.
13. Company Data by Operating and Geographic Segment
The Company has three reportable segments: Pharmaceuticals, Consumer Health Care
and Corporate. The Company's Pharmaceuticals and Consumer Health Care reportable
segments are strategic business units that offer different products and
services. The reportable segments are managed separately because they
manufacture, distribute and sell distinct products and provide services, which
require various technologies and marketing strategies. The Company is not
dependent on any single customer or major group of customers for its net revenue
(see Note 1).
The Pharmaceuticals segment manufactures, distributes and sells branded and
generic human ethical pharmaceuticals, biologicals, nutritionals, and animal
biologicals and pharmaceuticals. Principal products include women's health care
products, neuroscience therapies, cardiovascular products, infant nutritionals,
gastroenterology drugs, anti-infectives, vaccines, biopharmaceuticals, oncology
therapies, musculoskeletal therapies, hemophilia treatments and immunological
products. Principal animal health products include vaccines, pharmaceuticals,
endectocides and growth implants.
The Consumer Health Care segment manufactures, distributes and sells
over-the-counter health care products whose principal products include
analgesics, cough/cold/allergy remedies, nutritional supplements, herbal
products, and hemorrhoidal, antacid, asthma and other relief items.
Corporate is responsible for the treasury, tax and legal operations of the
Company's businesses and maintains and/or incurs certain assets, liabilities,
expenses, gains and losses related to the overall management of the Company
which are not allocated to the other reportable segments.
The accounting policies of the segments described above are the same as those
described in "Summary of Significant Accounting Policies" in Note 1. The Company
evaluates the performance of the Pharmaceuticals and Consumer Health Care
reportable segments based on income from continuing operations before taxes
which includes goodwill amortization, gains on the sales of non-corporate assets
and certain other items. Corporate includes special charges, interest expense
and interest income, gains on the sales of investments and other corporate
assets, including the sale of Immunex common stock, the Warner-Lambert Company
termination fee, certain litigation provisions, including the Redux and Pondimin
litigation charges, goodwill impairment and other miscellaneous items.
57
Company Data by Operating Segment
(In millions)
Years Ended December 31, 2001 2000 1999
- --------------------------------------------------------------------------------------------------
Net Revenue from Customers(1)
Pharmaceuticals $ 11,716.5 $ 10,772.6 $ 9,469.7
Consumer Health Care 2,412.0 2,441.1 2,345.4
--------------------------------------
Consolidated Total $ 14,128.5 $ 13,213.7 $ 11,815.1
======================================
Income (Loss) from Continuing Operations before Taxes(2)
Pharmaceuticals $ 3,503.5 $ 2,919.5 $ 2,538.6
Consumer Health Care 592.1 626.6 594.6
Corporate(3) (1,226.9) (4,647.1) (5,040.5)
--------------------------------------
Consolidated Total $ 2,868.7 $ (1,101.0) $ (1,907.3)
======================================
Depreciation and Amortization Expense
Pharmaceuticals $ 539.1 $ 458.8 $ 465.6
Consumer Health Care 53.1 61.0 57.3
Corporate 15.5 15.2 18.3
--------------------------------------
Consolidated Total $ 607.7 $ 535.0 $ 541.2
======================================
Expenditures for Long-Lived Assets
Pharmaceuticals $ 1,827.7 $ 1,720.1 $ 1,038.9
Consumer Health Care 67.8 38.4 66.8
Corporate 178.0 55.0 31.4
--------------------------------------
Consolidated Total $ 2,073.5 $ 1,813.5 $ 1,137.1
======================================
Total Assets at December 31,
Pharmaceuticals (4) $ 13,820.3 $ 12,388.6 $ 11,101.4
Consumer Health Care 1,736.3 1,697.2 1,864.4
Net assets - discontinued business held for sale -- -- 4,192.3
Corporate 7,411.3 7,006.7 5,965.7
--------------------------------------
Consolidated Total $ 22,967.9 $ 21,092.5 $ 23,123.8
======================================
Company Data by Geographic Segment
(In millions)
Years Ended December 31, 2001 2000 1999
- --------------------------------------------------------------------------------------------------
Net Revenue from Customers(1)(5)
United States $ 9,029.0 $ 8,045.1 $ 7,214.2
United Kingdom 694.4 898.1 745.1
Other International 4,405.1 4,270.5 3,855.8
--------------------------------------
Consolidated Total $ 14,128.5 $ 13,213.7 $ 11,815.1
======================================
Long-Lived Assets at December 31,(5)
United States $ 7,583.4 $ 6,228.8 $ 6,379.7
Ireland 652.7 386.2 326.8
Other International 2,482.6 2,688.6 2,498.0
--------------------------------------
Consolidated Total $ 10,718.7 $ 9,303.6 $ 9,204.5
======================================
(1) 2000 and 1999 were restated to reflect the early adoption of new
authoritative accounting guidance as of January 1, 2001 reflecting certain
rebates and sales incentives (i.e., coupons and other rebate programs) as
reductions of revenues instead of selling and marketing expenses.
(2) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001, 2000 and 1999 as follows: Pharmaceuticals--$136.8,
$147.8 and $154.3 and Consumer Health Care--$23.7, $31.8 and $32.7,
respectively.
58
(3) 2001, 2000 and 1999 Corporate included litigation charges of $950.0,
$7,500.0 and $4,750.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drug products Redux or
Pondimin. The charges provide for all anticipated payments in connection
with the nationwide, class action settlement, anticipated costs to resolve
the claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right, costs to resolve the
claims of PPH claimants and initial opt out claimants, and administrative
and litigation expenses, net of insurance (see Note 12). The charges
related to the Pharmaceuticals operating segment.
2000 Corporate also included:
o Income of $1,709.4 resulting from the receipt of a $1,800.0
termination fee provided for under the merger agreement with
Warner-Lambert Company offset, in part, by certain related expenses
(see Note 3).
o Income of $2,061.2 relating to the Company selling a portion of its
investment in Immunex common stock in a public equity offering with
Immunex (see Note 2). The transaction related to the Pharmaceuticals
operating segment.
o Goodwill impairment of $401.0 related to the goodwill associated with
generic pharmaceuticals and the Solgar consumer health care product
line. The charge related to the operating segments as follows:
Pharmaceuticals--$231.0 and Consumer Health Care--$170.0 (see Note 3).
o A special charge of $80.0 related to the voluntary ceasing of
production and subsequent market withdrawal of products containing PPA
(see Note 3). The charge related to the Consumer Health Care operating
segment.
o A special charge of $267.0 related to costs associated with certain
product discontinuations (see Note 3). The charge related to the
Pharmaceuticals operating segment.
1999 Corporate also included a special charge of $82.0 related to the
suspension of shipments and the voluntary market withdrawal of RotaShield,
the Company's rotavirus vaccine (see Note 3). The charge related to the
Pharmaceuticals operating segment.
(4) 2001 and 2000 included an equity investment in Immunex of $845.4 and
$759.2, respectively. Immunex was a consolidated subsidiary in 1999.
(5) Other than the United States and the United Kingdom, no other country in
which the Company operates had net revenue of 5% or more of the respective
consolidated total. Other than the United States and Ireland, no country in
which the Company operates had long-lived assets of 5% or more of the
respective consolidated total. The basis for attributing net revenue to
geographic areas is the location of the customer. Long-lived assets consist
of property, plant and equipment, goodwill and other intangibles, and other
assets, excluding deferred taxes, net investments in equity companies and
other investments.
14. Subsequent Events
The following events / transactions took place subsequent to the filing of the
Company's 2001 Form 10-K on March 29, 2002. These additional disclosures are
required in this Annual Report on Form 10-K/A filing as the audit opinion of
PricewaterhouseCoopers LLP contained herein is dated subsequent to March 29,
2002.
Acquisition of Immunex by Amgen
Prior to July 15, 2002, the Company was the beneficial owner of 223,378,088
shares of common stock of Immunex. On July 15, 2002, Amgen completed its
acquisition of Immunex. Under the terms of the acquisition agreement, each share
of Immunex common stock was exchanged for 0.44 shares of Amgen common stock and
$4.50 in cash. Accordingly, the Company received 98,286,358 shares of Amgen
common stock (representing approximately 7.7% of Amgen's outstanding common
stock) and $1,005.2 million in cash in exchange for all of its shares of Immunex
common stock, which had a book value of $867.7 million at July 15, 2002. The
Company has valued its shares of Amgen common stock at $2,500.1 million, which
is based on the quoted market price in effect as of July 15, 2002 reduced by an
overall discount of approximately 18%. The
59
discount rate was based on valuations provided by independent valuation
consultants in light of the various restrictions on the stock's marketability
referred to below.
The gain of $2,627.6 million ($1,684.7 million after-tax) on the exchange was
recorded during the 2002 third quarter and was calculated as follows:
(In millions)
-------------
Value received:
Cash $1,005.2
Amgen common stock 2,500.1
-------------
3,505.3
Less:
Equity investment in Immunex 867.7
Transaction costs 10.0
-------------
877.7
Gain before federal taxes 2,627.6
Provision for federal taxes 942.9
-------------
Net gain $1,684.7
=============
Pursuant to the terms of the acquisition, the Company and Amgen agreed to
certain standstill, voting, lock-up and sales volume limitation provisions with
respect to the Amgen common stock received by the Company. These provisions
prohibited the Company, without the consent of Amgen, from disposing of greater
than an aggregate of 20,000,000 shares of Amgen common stock in any calendar
quarter, with certain exceptions, including the right to request a limited
number of underwritten offerings.
On December 9, 2002 the Company filed a Current Report on Form 8-K to disclose
the sale of a significant amount of its Amgen common stock holdings. Following
the expiration of the 90-day lock-up period, during which the Company had agreed
to not sell any of its shares of Amgen common stock, the Company commenced
selling its shares of Amgen common stock, and in the fourth quarter, obtained
the consent of Amgen to exceed the sale limitation for such quarter. As of
December 9, 2002 the Company has sold 48,750,000 shares of Amgen common stock
generating gross proceeds of $2,300.0 million. As of December 9, 2002 the
Company's remaining shares of Amgen common stock total 49,536,358.
The Company and Amgen continue to co-promote Enbrel in the United States and
Canada with the Company having exclusive international rights to Enbrel. The
financial aspects of the existing licensing and marketing rights to Enbrel
remain unchanged.
60
Contingencies and Litigation Settlement
On July 9, 2002, findings from the Women's Health Initiative (WHI) study
evaluating hormone replacement therapy were released and the subset of the study
involving use of the Company's Prempro product was stopped early. This subset
was stopped early because, according to the predefined stopping rule, the
increased risk of breast cancer and cardiovascular events exceeded the specified
long-term benefits. Since that announcement, the Company has been named in
eleven putative class action lawsuits. Three of the eleven putative class
actions seek to represent a nationwide class of all women who have ever
purchased or ingested Prempro and seek, on behalf of the class, purchase price
refunds, personal injury damages, medical monitoring expenses and an order
requiring the Company to inform the public of the reported risks of Prempro.
Five putative class actions each seek to represent a statewide class of women
who have ingested the drug and seek purchase price refunds and medical
monitoring expenses. The remaining three putative class actions have been
voluntarily dismissed. An additional nine cases claiming personal injury damages
have been filed on behalf of allegedly injured individuals. The Company expects
that additional Prempro cases may be filed in the future. At this time, the
Company is unable to determine any possible range of loss relating to the
Prempro litigation and has not established any reserve with respect to any such
litigation, but expects to incur costs in connection with the defense of the
Prempro litigation. The Company believes it has meritorious defenses against
these claims and intends to vigorously defend any Prempro litigation.
The nationwide class action settlement to resolve litigation brought against the
Company regarding use of the diet drugs Pondimin (which in combination with
phentermine, a product that was not manufactured, distributed or sold by the
Company, was commonly referred to as "fen-phen") or Redux received final
judicial approval effective January 3, 2002. The Company recorded an initial
litigation charge of $4,750.0 million, net of insurance, in connection with the
Redux and Pondimin litigation in 1999, an additional charge of $7,500.0 million
in 2000, a third litigation charge of $950.0 million in the 2001 third quarter
and a fourth charge of $1,400.0 million in the 2002 third quarter. The principal
reason for the charge taken in the 2002 third quarter was that the volume and
size of the claims filed in the nationwide diet drug settlement were greater
than anticipated.
These charges are intended to cover the total amount required to resolve all
diet drug litigation, including anticipated funding requirements for the
nationwide class action settlement, anticipated costs to resolve the claims of
any members of the settlement class who in the future may exercise an
intermediate or back-end opt out right, costs to resolve the claims of primary
pulmonary hypertension (PPH) claimants and initial opt out claimants, and
administrative and litigation expenses.
Under the terms of the nationwide class action settlement, the period during
which class members could register to receive a screening echocardiogram from
the settlement trust ended on August 1, 2002. Those echocardiograms, as well as
echocardiograms that class members choose to receive on their own outside the
settlement, must be completed by
61
January 3, 2003, unless that date is extended by the court. Class members whose
echocardiograms demonstrate FDA-positive levels of heart valve regurgitation
(mild or greater aortic valve regurgitation or moderate or greater mitral valve
regurgitation) must elect either to remain in the settlement or to withdraw from
the settlement and proceed as an intermediate opt-out (with specific rights and
limitations defined in the settlement) by May 3, 2003.
Based upon the information available at this time, the Company believes that the
balance remaining in its reserves will be adequate to cover the remaining
obligations relating to the diet drug litigation. However, in light of the
inherent uncertainty in estimating litigation exposure it is possible that
additional reserves will be required.
In the opinion of the Company, although the outcome of any legal proceedings
cannot be predicted with certainty, the ultimate liability of the Company in
connection with its legal proceedings will not have a material adverse effect on
the Company's financial position but could be material to the results of
operations or cash flows in any one accounting period.
62
Report of Independent Accountants
To the Board of Directors and Stockholders of Wyeth:
In our opinion, the accompanying consolidated balance sheet as of December 31,
2001 and the related consolidated statements of operations, of changes in
stockholders' equity and of cash flows present fairly, in all material respects,
the financial position of Wyeth and its subsidiaries at December 31, 2001, and
the results of their operations and their cash flows for the year then ended in
conformity with accounting principles generally accepted in the United States of
America. These financial statements are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements based on our audit. We conducted our audit of these statements in
accordance with auditing standards generally accepted in the United States of
America, which require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audit provides a reasonable basis for our opinion. The financial statements of
the Company as of December 31, 2000 and for each of the two years in the period
ended December 31, 2000 were audited by other independent accountants who have
ceased operations. Those independent accountants expressed an unqualified
opinion on those statements in their report dated January 24, 2002.
As discussed above, the financial statements of Wyeth as of December 31, 2000,
and for each of the two years in the period ended December 31, 2000, were
audited by other independent accountants who have ceased operations. As
described in Note 1, these financial statements have been revised to include the
transitional disclosures required by Statement of Financial Accounting Standards
No. 142, "Goodwill and Other Intangible Assets", which was adopted by the
Company as of January 1, 2002. We audited the transitional disclosures described
in Note 1. In our opinion, the transitional disclosures for 2000 and 1999 in
Note 1 are appropriate. However, we were not engaged to audit, review, or apply
any procedures to the 2000 or 1999 financial statements of the Company other
than with respect to such disclosures and, accordingly, we do not express an
opinion or any other form of assurance on the 2000 or 1999 financial statements
taken as a whole.
PricewaterhouseCoopers LLP
Florham Park, NJ
November 26, 2002,
except for paragraph 5 of Note 14
which is as of December 9, 2002
63
The following is a copy of a report issued by Arthur Andersen LLP and included
in the 2001 Form 10-K report filed on March 29, 2002. This report has not been
reissued by Arthur Andersen LLP and Arthur Andersen LLP has not consented to its
use in this Annual Report on Form 10-K/A.
To the Board of Directors and Stockholders of Wyeth:
We have audited the accompanying consolidated balance sheets of Wyeth
(formerly American Home Products Corporation--a Delaware corporation) and
subsidiaries as of December 31, 2001* and 2000, and the related consolidated
statements of operations, changes in stockholders' equity and cash flows for
each of the three years in the period ended December 31, 2001*. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Wyeth and subsidiaries as of
December 31, 2001* and 2000, and the results of their operations and cash flows
for each of the three years in the period ended December 31, 2001* in conformity
with accounting principles generally accepted in the United States.
Arthur Andersen LLP
New York, New York
January 24, 2002
* Subsequent to the date of this report, the consolidated balance sheet as of
December 31, 2001 and the related consolidated statements of operations, changes
in stockholders' equity and cash flows for the year then ended were audited by
PricewaterhouseCoopers LLP whose report appears on page 63 of this Annual Report
on Form 10-K/A.
64
Quarterly Financial Data (Unaudited)
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2001 2001 2001 2001
- ------------------------------------------------------------------------------------------------------------------
Net revenue $ 3,449,176 $ 3,216,420 $ 3,736,250 $ 3,726,668
Gross profit 2,650,573 2,425,379 2,856,328 2,807,458
Income from continuing operations (1) 733,554 476,996 252,072 822,672
Diluted earnings per share from
continuing operations (1) 0.55 0.36 0.19 0.62
Net income (1) 733,554 476,996 252,072 822,672
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2000 2000 2000 2000
- ------------------------------------------------------------------------------------------------------------------
Net revenue (2) $ 3,195,852 $ 3,026,215 $ 3,503,605 $ 3,487,999
Gross profit (2) 2,413,860 2,255,173 2,658,346 2,616,874
Income (loss) from continuing operations (1)(3) 1,746,009 412,734 762,100 (3,821,883)
Diluted earnings (loss) per share from
continuing operations (1)(3)(4) 1.32 0.31 0.58 (2.91)
Net income (loss) (1)(3)(5) 276,362 412,734 762,100 (3,821,883)
(1) Third Quarter 2001 and Fourth Quarter 2000 included litigation charges of
$615,000 after-tax and $0.46 per share-diluted and $5,375,000 after-tax and
$4.10 per share-diluted, respectively, in connection with litigation
brought against the Company regarding the use of the diet drugs Redux or
Pondimin.
Fourth Quarter 2000 also included:
o Income of $1,414,859 after-tax and $1.08 per share-diluted related to
the Company selling a portion of its investment in Immunex common stock in
a public equity offering with Immunex.
o Goodwill impairment of $341,000 after-tax and $0.26 per share-diluted
related to the goodwill associated with generic pharmaceuticals and the
Solgar consumer health care product line.
o A special charge of $52,000 after-tax and $0.04 per share-diluted
related to the voluntary ceasing of production and subsequent voluntary
market withdrawal of products containing PPA.
o A special charge of $173,000 after-tax and $0.13 per share-diluted
related to costs associated with certain product discontinuations.
(2) First, Second, Third and Fourth Quarters 2000 were restated to reflect the
early adoption of new authoritative accounting guidance as of January 1,
2001 reflecting certain rebates and sales incentives (i.e., coupons and
other rebate programs) as reductions of revenues instead of selling and
marketing expenses.
(3) First Quarter 2000 included income of $1,111,097 after-tax and $0.84 per
share-diluted resulting from the receipt of a $1,800,000 termination fee
provided for under the merger agreement with Warner-Lambert Company offset,
in part, by certain related expenses.
(4) The weighted average common shares outstanding for diluted loss per share
for the Fourth Quarter 2000 did not include common stock equivalents, as
the effect would have been antidilutive. In addition, the sum of the 2000
diluted earnings (loss) per share from continuing operations did not equal
the full year 2000 diluted loss per share from continuing operations for
the same reason.
(5) As of the 2000 First Quarter, the Company reflected the Cyanamid
Agricultural Products business, which was sold on June 30, 2000, as a
discontinued operation and recorded a loss on disposal of such business of
$1,572,993, net of tax charges of $855,248.
65
Report of Independent Accountants
To the Board of Directors and Stockholders of Wyeth:
Our audit of the consolidated financial statements referred to in our report
dated November 26, 2002, except for paragraph 5 of Note 14 which is as of
December 9, 2002, appearing in this Annual Report on Form 10-K/A of Wyeth also
included an audit of the financial statement schedule listed in Item 15(a)2 of
this Form 10-K/A. In our opinion, this financial statement schedule presents
fairly, in all material respects, the information set forth therein when read in
conjunction with the related consolidated financial statements. The 2000 and
1999 financial statement schedule information of the Company was audited by
other independent accountants who have ceased operations. Those independent
accountants expressed an unqualified opinion on that financial statement
schedule information in their report dated January 24, 2002.
PricewaterhouseCoopers LLP
Florham Park, NJ
November 26, 2002
The following is a copy of a report issued by Arthur Andersen LLP and included
in the 2001 Form 10-K report filed on March 29, 2002. This report has not been
reissued by Arthur Andersen LLP and Arthur Andersen LLP has not consented to its
use in this Annual Report on Form 10-K/A.
To the Board of Directors and Stockholders of Wyeth:
We have audited in accordance with auditing standards generally accepted
in the United States, the consolidated financial statements included in Wyeth's
(formerly American Home Products Corporation - a Delaware Corporation) Annual
Report to Stockholders incorporated by reference in this Form 10-K, and have
issued our report thereon dated January 24, 2002. Our audit was made for the
purpose of forming an opinion on those statements taken as a whole. The
schedule* listed in the accompanying index is the responsibility of the
Company's management and is presented for purposes of complying with the
Securities and Exchange Commission's rules and is not part of the basic
financial statements. The schedule* has been subjected to the auditing
procedures applied in the audit of the basic financial statements and, in our
opinion, fairly states in all material respects the financial data required to
be set forth therein in relation to the basic financial statements taken as a
whole.
Arthur Andersen LLP
New York, New York
January 24, 2002
* Subsequent to the date of this report, the 2001 financial statement
schedule information was audited by PricewaterhouseCoopers LLP whose report
appears above.
66
Wyeth and Subsidiaries
Schedule II - Valuation and Qualifying Accounts For the
Years Ended December 31, 2001, 2000 and 1999
(Dollars in thousands)
Column A Column B Column C Column C Column D Column E
1 2
Balance Balance
at Additions- at
Beginning Charged to Adjustments Deductions End
of Period Expense (A) (B) of Period
--------- ---------- ----------- ---------- ---------
Description
Year ended 12/31/01:
Allowance for doubtful accounts $ 114,003 $ 17,257 $ - $ 31,960 $ 99,300
Allowance for cash discounts 30,147 219,995 - 218,708 31,434
--------- ---------- ----------- ---------- ---------
Total accounts receivable allowances $ 144,150 $ 237,252 $ - $ 250,668 $ 130,734
========= ========== =========== ========== =========
Allowance for deferred tax assets $ 51,153 $ - $ - $ 1,571 $ 49,582
========= ========== =========== ========== =========
Year ended 12/31/00:
Allowance for doubtful accounts $ 113,640 $ 30,187 $ 94 $ 29,918 $ 114,003
Allowance for cash discounts 28,119 204,032 (1,787) 200,217 30,147
--------- ---------- ----------- ---------- ---------
Total accounts receivable allowances $ 141,759 $ 234,219 $ (1,693) $ 230,135 $ 144,150
========= ========== =========== ========== =========
Allowance for deferred tax assets $ 151,409 $ 74 $ (100,330) $ - $ 51,153
========= ========== =========== ========== =========
Year ended 12/31/99 (C):
Allowance for doubtful accounts $ 123,650 $ 32,779 $ - $ 42,789 $ 113,640
Allowance for cash discounts 27,927 204,533 - 204,341 28,119
--------- ---------- ----------- ---------- ---------
Total accounts receivable allowances $ 151,577 $ 237,312 $ - $ 247,130 $ 141,759
========= ========== =========== ========== =========
Allowance for deferred tax assets $ 237,174 $ 13,005 $ - $ 98,770 $ 151,409
========= ========== =========== ========== =========
(A) Represents an increase to the beginning balance as a result of the
consolidation of pharmaceutical operations in India and Japan, effective
January 1, 2000, which were previously accounted for on an equity basis.
Also, the beginning balance relating to Immunex, which was deconsolidated
effective January 1, 2000, was excluded.
(B) Represents amounts used for the purposes for which the accounts were created
and reversal of amounts no longer required.
(C) As a result of the sale of the Cyanamid Agricultural Products business on
June 30, 2000, amounts for 1999 were restated, to reflect the business as a
discontinued operation.
67
SIGNATURE
---------
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this Annual Report on Form 10-K/A to
be signed on its behalf by the undersigned, thereunto duly authorized.
WYETH
-----
(Registrant)
December 23, 2002 By /S/ Kenneth J. Martin
-------------------------
Kenneth J. Martin
Executive Vice President
and Chief Financial Officer
68
Certifications
--------------
I, Robert Essner, certify that:
1. I have reviewed this Annual Report on Form 10-K/A of Wyeth;
2. Based on my knowledge, this Annual Report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this Annual Report;
3. Based on my knowledge, the financial statements, and other financial
information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this Annual Report.
Dated: December 23, 2002 By /s/ Robert Essner
-----------------------------
Robert Essner
President and Chief Executive
Officer
69
Certifications
--------------
I, Kenneth J. Martin, certify that:
1. I have reviewed this Annual Report on Form 10-K/A of Wyeth;
2. Based on my knowledge, this Annual Report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to
the period covered by this Annual Report;
3. Based on my knowledge, the financial statements, and other financial
information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this Annual Report.
Dated: December 23, 2002 By /s/ Kenneth J. Martin
---------------------------
Kenneth J. Martin
Executive Vice President
and Chief Financial Officer
70
Exhibit Index
-------------
Exhibit No. Description
----------- -----------
(23.2) Consent of Independent Accountants,
PricewaterhouseCoopers LLP, relating to their report
dated November 26, 2002, except for paragraph 5 of
Note 14 which is as of December 9, 2002, consenting to
the incorporation thereof in Registration Statements
on Form S-3 (File Nos. 33-45324 and 33-57339), Form
S-4 (File No. 333-59642) and on Form S-8 (File Nos.
2-96127, 33-24068, 33-41434, 33-53733, 33-55449,
33-45970, 33-14458, 33-50149, 33-55456, 333-15509,
333-76939, 333-67008, 333-64154 and 333-59668) by
reference to the Form 10-K/A of the Company filed for
the year ended December 31, 2001.
(99.4) Certification pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
(99.5) Certification pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.
71